Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒☒

As of ~~August 12, 2021,~~May 10, 2022, the registrant had ~~97,732,079~~101,114,861 shares of common stock, ~~$0.001~~$0.0001 par value per share, outstanding.

Certain statements contained herein, as well as in other filings we make with the United States Securities and Exchange Commission (“SEC”) and other written and oral information we release, regarding our future performance constitute "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements may relate to, among other things, the impact on our business, operations and financial results of the COVID-19 pandemic (which, among other things, may affect many of the items listed below); the demand for our products and services; revenue growth; effects of competition; supply chain and technology initiatives; inventory and in-stock positions; state of the economy; state of the credit markets, including mortgages, home equity loans, and consumer credit; impact of tariffs; demand for credit offerings; management of relationships with our employees, suppliers and vendors, and customers; international trade disputes, natural disasters, public health issues (including pandemics and related quarantines, shelter-in-place orders, and similar restrictions), and other business interruptions that could disrupt supply or delivery of, or demand for, our products or services; continuation of equity programs; net earnings performance; earnings per share; capital allocation and expenditures; liquidity; return on invested capital; expense leverage; stock-based compensation expense; commodity price inflation and deflation; the ability to issue debt on terms and at rates acceptable to us; the impact and expected outcome of investigations, inquiries, claims, and litigation; the effect of accounting charges; the effect of adopting certain accounting standards; the impact of regulatory changes; financial outlook; and the integration of acquired companies into our organization and the ability to recognize the anticipated synergies and benefits of those acquisitions.

Forward-looking statements are based on currently available information and our current assumptions, expectations and projections about future events. You should not rely on our forward-looking statements. These statements are not guarantees of future performance and are subject to future events, risks and uncertainties – many of which are beyond our control, dependent on the actions of third parties, or currently unknown to us – as well as potentially inaccurate assumptions that could cause actual results to differ materially from our expectations and projections. These risks and uncertainties include, but are not limited to, those described in Part II, Item 1A, "Risk Factors" and elsewhere in this report and as also may be described from time to time in future reports we file with the SEC. You should read such information in conjunction with our Condensed Consolidated Financial Statements and related notes and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in this report. There also may be other factors that we cannot anticipate or that are not described in this report, generally because we do not currently perceive them to be material. Such factors could cause results to differ materially from our expectations.

Forward-looking statements speak only as of the date they are made, and we do not undertake to update these statements other than as required by law. You are advised, however, to review any further disclosures we make on related subjects in our periodic filings with the SEC.

~~Condensed Consolidated Balance Sheets (Unaudited)~~CONDENSED CONSOLIDATED BALANCE SHEETS


	June 30,			December 31,			March 31,			December 31,
(in thousands, except share data)	2021			2020
(in thousands, except share and per share data)							2022			2021
Assets:
Current assets:
Cash and cash equivalents	$	416,355		$	377,581		$	210,045		$	286,487
Accounts receivable, net		10,069			6,605			18,825			17,149
Inventories		17,653			13,642
Other receivables, net								1,378			3,836
Inventories, net								28,230			24,573
Prepaid expenses and other current assets		4,611			3,089			4,059			4,737
Contract assets		3,018			1,466			4,305			3,576
Total current assets		451,706			402,383			266,842			340,358

Property, plant and equipment, net		159,983			106,795			364,635			316,181
Patents, net		1,819			1,801
Intangible assets, net								83,578			84,659
Goodwill								62,663			62,649
Right-of-use assets		16,546			19,387			19,179			19,240
Leverage loans receivable		13,408			13,408			13,408			13,408
Restricted cash		524			2,316			480			481
Loan fees		1,548			0			1,452			1,397
Other assets		71			111			228			224
Total assets	$	645,605		$	546,201		$	812,465		$	838,597

Liabilities and Stockholders' Equity:
Current liabilities:
Accounts payable	$	18,970		$	10,610		$	17,076		$	20,790
Accrued liabilities		5,901			9,220			14,042			18,777
Unearned revenue and contract liabilities		822			2,455			-			214
Current portion of lease liability		2,947			3,000			3,337			3,337
Current portion of long-term debt, net		333			25,201			218			357
Total current liabilities		28,973			50,486			34,673			43,475

Private warrants liability		59,302			82,860			4,583			9,578
Long-term lease liability, net		20,581			24,175			22,554			22,693
Long-term debt, net		29,576			31,386			261,459			260,934
Deferred income taxes								723			1,014
Other long-term liabilities		625			1,250			526			638
Total liabilities	$	139,057		$	190,157		$	324,518		$	338,332

Commitments and Contingencies (Note 14)
Commitments and Contingencies (Note 15)

Stockholders' equity:
Common stock, $0.0001 par value; 200,000,000 shares authorized: 97,732,079 and 84,535,640 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively	$	9		$	8
Common stock, $0.0001 par value; 200,000,000 shares authorized: 100,760,215 and 100,687,820 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively							$	10		$	10
Additional paid-in capital		620,808			414,819			633,213			619,145
Accumulated deficit		(114,269	)		(58,783	)		(145,276	)		(118,890	)
Total stockholders’ equity		506,548			356,044			487,947			500,265
Total liabilities and stockholders’ equity	$	645,605		$	546,201		$	812,465		$	838,597

The accompanying notes are an integral part of these ~~Condensed Consolidated Financial Statements.~~

~~Condensed Consolidated Statements of Operations (Unaudited)~~DANIMER SCIENTIFIC, INC.

The accompanying notes are an integral part of these ~~Condensed Consolidated Financial Statements.~~condensed consolidated financial statements.

~~Condensed Consolidated Statements of Stockholders' Equity (Unaudited)~~CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

The accompanying notes are an integral part of these ~~Condensed Consolidated Financial Statements.~~

~~Condensed Consolidated Statements of Cash Flows (Unaudited)~~CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

The accompanying notes are an integral part of these ~~Condensed Consolidated Financial Statements.~~

~~Danimer Scientific, Inc.~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Note 1. Basis of Presentation

Description of Business

Danimer Scientific, Inc. ~~(“Danimer”)~~, together with its subsidiaries ~~(collectively referred to as the “Company”~~(“Company”, “Danimer”, “we”, “us”, or “our”), is a performance polymer company specializing in bioplastic replacements for traditional petroleum-based plastics. Our common stock is listed on the New York Stock Exchange under the symbol “DNMR”.

The Company (formerly Live Oak Acquisition Corp. (“Live Oak”)), was originally incorporated in the State of Delaware on May 24, 2019 as a special purpose acquisition company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses. Live Oak completed its initial public offering in May 2020. On December 29, 2020, Live Oak consummated a business combination (“Business Combination”) pursuant to an Agreement and Plan of Merger, dated as of October 3, 2020 (as amended by Amendment No. 1, dated as of October 8, 2020, and Amendment No. 2, dated as of December 11, 2020 (collectively “Merger Agreement”), by and among Live Oak, Green Merger Corp. (“Merger Sub.”), and Meredian Holdings Group, Inc. (“Legacy Danimer”). Immediately upon consummation of the Business Combination, Merger Sub. merged with and into Legacy Danimer, with Legacy Danimer surviving the merger as a wholly owned subsidiary of Live Oak. In connection with the Business Combination, Live Oak changed its name to Danimer Scientific, Inc.

On August 11, 2021, we closed the acquisition of Novomer, Inc. (integrated into our business as “Danimer Catalytic Technologies”). Our consolidated results include those of Danimer Catalytic Technologies from the acquisition date forward. Refer to Note 2 for further discussion of the acquisition.

Financial Statements

~~We have prepared these~~The accompanying condensed consolidated financial statements ~~(“Financial Statements”)~~are prepared in accordance with accounting principles generally accepted in the United States (“~~U.S.~~ GAAP”) ~~for interim financial information~~ and ~~the rules~~consolidate all assets and ~~regulations~~liabilities of the ~~SEC. In~~Company and its wholly owned subsidiaries. GAAP requires us to make certain estimates and assumptions in recording assets, liabilities, sales and expenses as well as in the ~~opinion~~disclosure of ~~management, our Financial Statements reflect all adjustments, which are of a normal recurring nature, necessary~~contingent assets and liabilities. Actual results could differ from those estimates. All intercompany transactions and balances have been eliminated. Certain reclassifications have been made to present fairly our financial position, results of operations, stockholders’ equity, and cash flows at the dates and for the periods presented. Our Financial Statements should be read in conjunction with our audited consolidated financial statements and the notes thereto included in our Amended Annual Report on Form 10-K/A for the year ended December 31, 2020. Results for interim periods are not necessarily indicative of the results for the year.

~~We have made certain reclassifications to the prior period presentation in order~~previously reported amounts to conform to the current presentation.

We cannot predict the ongoing impact of the COVID-19 pandemic on the increased volatility in global economic and political environments, market demand for our products, supply chain disruptions, possible workforce availability, exchange rate and commodity price volatility and availability of financing, and their impact to our total revenue, production volumes, costs and overall financial condition and available funding. In preparing ~~our Financial Statements in conformity with U.S. GAAP,~~these condensed consolidated financial statements, we have considered and, where appropriate, ~~reflected~~included the effects of the COVID-19 pandemic on our operations. The pandemic continues to provide significant challenges to the U.S. and global economies.

Since we do 0t have any items of other comprehensive income or loss, there is no difference between net loss and comprehensive (loss) income for the three month periods ended March 31, 2022 or 2021, so a separate Statement of Comprehensive Income (Loss) that would otherwise be required is not presented.

Recently Issued ~~or Adopted~~ Accounting Pronouncements

There have been no new accounting pronouncements not yet effective ~~or adopted in the current period~~ that we believe will have a significant effect, or potential significant effect, on our ~~Financial Statements.~~condensed consolidated financial statements.

Note 2. Business Combination

~~Live Oak Acquisition Corp. (“Live Oak”) was incorporated~~Danimer Catalytic Technologies

On August 11, 2021, we acquired all of the outstanding shares of Novomer, Inc., a privately held company, in exchange for $153.9 million in cash, gross of cash acquired, subject to certain customary adjustments as set forth in the ~~State~~merger agreement. We also entered into employment or consulting agreements with, and granted stock options to, certain key employees and consultants of ~~Delaware on May 24, 2019~~Novomer Inc. We have also recorded contingent purchase price payable that will be payable to the sellers upon our collection of an income tax refund receivable.

Danimer Catalytic Technologies uses its proprietary thermal catalytic conversion process to produce a unique type of PHA, referred to under its brand name as Rinnovo, that can be incorporated into some of our products as a ~~special purpose~~complement to our existing PHA polymer at reduced cost.

The table below sets forth the preliminary fair values of assets acquired and liabilities assumedincludingtheadjustmentsrecordedinthethreemonthsendedMarch31,2022:


	December 31,						March 31,
(in thousands)	2021			Adjustments			2022
Cash and restricted cash	$	2,741		$	0		$	2,741
Property, plant and equipment		18,622			0			18,622
Other assets acquired		2,302			0			2,302
Right-of-use asset		2,715			0			2,715
Acquired technology		84,400			0			84,400
Goodwill		62,649			14			62,663
Deferred tax liability		(14,246	)		0			(14,246	)
Lease liability		(2,759	)		0			(2,759	)
Liabilities assumed		(2,004	)		(14	)		(2,018	)
Contingent purchase price payable		(500	)		0			(500	)
Total preliminary purchase price	$	153,920		$	0		$	153,920

We have recognized the assets acquired and liabilities assumed at their estimated acquisition ~~company formed~~date fair values, with the excess of the purchase price over the estimated fair values of the identifiable net assets acquired recorded as goodwill.

The accounting for the ~~purpose of effecting a~~ business combination ~~with one or more businesses. Live Oak completed its initial public offering in May 2020. On December 29, 2020, Live Oak consummated a~~is based on currently available information and is considered preliminary. The final accounting for the business combination ~~(“Business Combination”) with Meredian Holdings Group, Inc. (“Legacy Danimer”) with Legacy Danimer surviving~~may differ materially from that presented above as future events may provide additional information about the ~~merger as a wholly owned subsidiary~~realizability of ~~Live Oak.~~other assets or the existence of other liabilities at the acquisition date. In ~~connection with the Business Combination, Live Oak changed its name~~addition, income tax returns for 2021 have yet to ~~Danimer Scientific, Inc.~~be filed, and we are validating certain state income tax allocations, which could result in changes to acquisition-date deferred tax liability.

~~For financial accounting~~The preliminary estimated goodwill is attributable to the strategic opportunities and ~~reporting purposes, Legacy Danimer was deemed~~synergies that we expect to arise from the ~~accounting acquirer, Live Oak was treated as the accounting acquiree,~~acquisition and the ~~Business Combination was accounted~~value of its existing workforce. The goodwill is not deductible for ~~as a reverse recapitalization. Effectively, the Business Combination was treated as the equivalent of Legacy Danimer issuing stock~~federal income tax purposes.

The following table compares pro forma revenue and loss from operations for the ~~net assets~~combined entity for the three months ended March 31, 2021 as if the acquisition had taken place on January 1, 2021 to actual results for the three months ended March 31, 2022. These pro forma results do not necessarily reflect what the combined entity's results would have been had the acquisition taken place at that time, and this pro forma financial information may not be useful in predicting our future financial results. The actual results might have differed significantly from the pro forma amounts reflected herein due to a variety of ~~Live Oak, accompanied by a recapitalization. Under this method~~factors. The following includes pro forma adjustments to reflect amortization of ~~accounting,~~acquired technology intangible assets. We do not disclose pro forma impact related to income taxes or earnings-per-share as we do not believe those are useful to the ~~historical financial statements of Legacy~~reader in our situation.


	Three Months Ended March 31,
(in thousands)	2022			2021
Revenue	$	14,743		$	13,195
Loss from operations		(30,689	)		(13,672	)

During the three months ended March 31, 2022, Danimer are our historical financial statements. The net assets of Live Oak are stated at historical costs, with no goodwill or other intangible assets recorded, and were consolidated with Legacy Danimer’s financial statements on December 29, 2020.Catalytic Technologies incurred $2.9 million in expenses, including amortization expense.

Note 3. ~~Inventories~~Fair Value Considerations

Fair value is defined as the price we would receive to sell an asset in a timely transaction or pay to transfer a liability in a timely transaction with an independent buyer in the principal market, or in the absence of a principal market, the most advantageous market for the investment or liability. A framework is used for measuring fair value utilizing a three-tier hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs.

The three levels of the fair value hierarchy are as follows:

Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets and liabilities;

Level 2 - Observable inputs other than quoted prices in active markets, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data;

Level 3 - Unobservable inputs reflecting management’s assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.

Level 1

The carrying amounts of our cash and cash equivalents and restricted cash were measured using quoted market prices in active markets and represent Level 1 investments. Our other financial instruments such as accounts receivable, accounts payable and accrued expenses, approximate their fair values due to their short maturities. The carrying value of our long-term debt instruments also approximates fair value due to their recent issuance and/or near-term maturities.

We value our restricted stock that does not include market or performance factors at the closing price of a share of our common stock on the grant date, or $5.86 for such restricted stock granted during the three months ended March 31, 2022.

We value our restricted stock with performance factors at the closing price of a share of our common stock on each period end date, or $5.86 at March 31, 2022, since such grants include a cash settlement feature.

Level 2

We value our restricted stock that contain a market-based vesting provision using a Monte Carlo simulation, which takes into account a large number of potential stock price scenarios over time and incorporates varied assumptions about volatility and exercise behavior for those various scenarios. These assumptions are based on market data but cannot be directly observed. A fair value is determined for each potential outcome. There were 0 restricted stock units that contained a market-based vesting condition issued during the three months ended March 31, 2022.

Level 3

We use the Black-Scholes option pricing model to value stock options, including ESPP awards, and our outstanding warrants to purchase shares of our common stock at an exercise price of $11.50 per share, subject to adjustments, that had been privately placed prior to the Business Combination (“Private Warrants”). The Private Warrants and stock options with a cash-settlement feature are re-valued each period end, and all other stock options are valued on the date of grant only. Other than this mark to market factor, we recognize this expense on a straight-line basis over the respective vesting periods. Since our stock price history as a publicly traded company is shorter in duration than the expected lives of our options (other than ESPP awards), we use a peer group to assess volatility. We have not paid and do not currently anticipate paying a cash dividend on our common stock, so we have set the expected annual dividend yield to zero for all calculations. We used risk-free rates equal to the U.S. Treasury yield curves in effect as of the valuation dates for durations equal to the expected lives of each option. We use the simplified method under Staff Accounting Bulletin Topic 14, defined as the mid-point between the vesting period and the contractual term for each grant, to determine the expected lives of stock options and we use the remaining contractual life of the warrants as their expected life.

~~Inventories consisted~~The following table sets forth the fair values we calculated and the ranges of values used in our Black Scholes calculations for stock options, other than ESPP awards.


	March 31,	Three Months Ended March 31,
	2022	2022	2021
Share prices of our common stock	$5.86	$3.88 - $5.86	$22.41 - $64.29
Expected volatilities	44.74%	44.42% - 48.51%	41.50% - 41.50%
Risk-free rates of return	2.38%	1.66% - 2.39%	1.05% - 1.05%
Expected option terms (years)	5.31	5.31 - 6.00	6.00 - 6.00
Calculated option values	$2.68	$0.69 - $3.44	$18.52 - $18.52

The table below sets forth the ~~following:~~ inputs we used in our Black Scholes models for Private Warrants valuations and the fair values determined.

June 30,

December 31,

(in thousands)

2021

2020

Raw materials

$
7,650

$
6,825

Work in progress

0

133

Finished goods and related items

10,003

6,684

Total inventories

$
17,653

$
13,642


	March 31, 2022			December 31, 2021
Share price of our common stock	$	5.86		$	8.52
Expected volatility		49.4	%		47.6	%
Risk-free rate of return		2.41	%		1.11	%
Expected warrant term (years)		3.75			3.99
Fair value determined per warrant	$	1.17		$	2.45

Note 4. Inventories, net

Inventories, net consisted of the following:


	March 31,		December 31,
(in thousands)	2022		2021
Raw materials	$	13,428	$	11,555
Work in process		989		928
Finished goods and related items		13,813		12,090
Total inventories, net	$	28,230	$	24,573

At March 31, 2022 and December 31, 2021, finished goods and related items included $6.5 million and $5.6 million of finished neat PHA. Inventory at March 31, 2022 is stated net of reserves of $1.1 million related to interim assessments to reduce the carrying value of inventory to its fair value.

Note 5. Property, Plant and Equipment, net

Property, plant and equipment, net, consisted of the following:

Estimated

Useful Life

June 30,

December 31,

(in thousands)

(Years)

2021

2020

Land and improvements

20

$
92

$
92

Leasehold improvements

Shorter of useful
life or lease term

21,021

20,932

Buildings

15-40

2,089

2,089

Machinery and equipment

5-20

82,489

64,164

Motor vehicles

7-10

874

693

Furniture and fixtures

7-10

229

221

Office equipment

3-10

2,110

2,089

Construction in progress

N/A

74,771

36,146

183,675

126,426

Accumulated depreciation and amortization

(23,692
)

(19,631
)
Property, plant and equipment, net

$
159,983

$
106,795


(in thousands)	Estimated Useful Life (Years)	March 31, 2022			December 31, 2021
Land and improvements	20	$	92		$	92
Leasehold improvements	Shorter of useful life or lease term		27,893			27,845
Buildings	15-40		2,156			2,156
Machinery and equipment	5-20		99,716			97,923
Motor vehicles	7-10		912			912
Furniture and fixtures	7-10		433			420
Office equipment	3-10		3,467			3,368
Construction in progress	N/A		262,226			212,647
			396,895			345,363
Accumulated depreciation and amortization			(32,260	)		(29,182	)
Property, plant and equipment, net		$	364,635		$	316,181

We reported depreciation and amortization expense (which included amortization of ~~patents)~~intangible assets) as follows:


	Three Months Ended June 30,				Six Months Ended June 30,				Three Months Ended March 31,
(in thousands)	2021		2020		2021		2020		2022		2021
Cost of revenue	$	1,951	$	753	$	3,790	$	1,436	$	2,227	$	1,839
Selling, general and administrative		177		31		273		60		161		96
Research and development		83		155		248		313		1,871		165
Total depreciation and amortization expense	$	2,211	$	939	$	4,311	$	1,809	$	4,259	$	2,100

Construction in progress consists primarily of the ~~conversion and~~ build-out of our ~~new~~ facility in Winchester, ~~Kentucky.~~Kentucky and early phases of construction of our new plant in Bainbridge, Georgia. Property, plant and equipment includes gross capitalized interest of $~~5.3~~7.3 million and $~~5.1~~5.7 million as of ~~June 30, 2021~~March 31, 2022 and December 31, ~~2020,~~2021, respectively. For the three ~~and six~~ months ended ~~June 30,~~March 31, 2022 and 2021, ~~and 2020,~~ interest costs of $~~0.1~~1.6 million and $~~0.3~~ ~~million and $1.1~~ ~~million and $1.8~~0.2 million, respectively, were capitalized to property, plant and equipment. ~~At December 31, 2020, prepaid expenses and other current assets included $0.8~~ ~~million of equipment classified as held for sale. We sold this equipment in April 2021 at a loss of approximately $~~33 ~~thousand.~~

Note ~~5. Patents~~6. Intangible Assets and Goodwill

~~The majority~~Intangible Assets

Our recognized intangible assets consist of ~~our~~patents and the unpatented technological know-how of Danimer Catalytic Technologies. Our legacy patents were ~~purchased from another commercial corporation, but we have also developed our own patents.~~ initially recorded at cost. The values of Danimer Catalytic Technologies' patents and unpatented know-how are inseparable and represent their acquisition-date fair value, less subsequent amortization.

We capitalize patent defense and application costs. Patent costs are amortized on a straight-line basis over their estimated useful lives, which range from 13 to 16 years. ~~At June 30, 2021 and December 31, 2020,~~The Danimer Catalytic Technologies patents are amortized over its estimated 20 year life. Our intangible portfolio has an estimated weighted average useful life of 19.8years.

Intangible assets, net, consisted of the ~~gross carrying value~~following:


	March 31,			December 31,
(in thousands)	2022			2021
Intangible assets, gross	$	93,344		$	93,244
Capitalized patent costs not yet subject to amortization		971			869
Intangible assets subject to amortization, gross		92,373			92,375
Accumulated amortization		(9,766	)		(8,585	)
Intangible assets subject to amortization, net		82,607			83,790
Total intangible assets, net	$	83,578		$	84,659

Amortization expense of ~~patents subject to amortization was approximately~~ $~~7.8~~ ~~million. Accumulated amortization was approximately $6.7~~1.2 million and $~~6.5~~ ~~million at June 30, 2021 and December 31, 2020, respectively. Amortization expense was $~~0.1 million, ~~and $0.2~~ ~~million for~~respectively, during the three ~~and six~~ months ended ~~June 30,~~March 31, 2022 and 2021 ~~and 2020 and is~~was included in research and development costs. ~~At June 30, 2021 and December 31, 2020, capitalized patent acquisition and defense costs not yet subject to amortization~~

Goodwill

Changes in the carrying amount of goodwill were $as follows:~~0.7~~


	March 31,
(in thousands)	2022
Balance at beginning of year	$	62,649
Adjustment of estimate of fair value of liabilities assumed related to Danimer Catalytic Technologies acquisition		14
Balance at end of year	$	62,663

Note 6.7. Accrued Liabilities

The components of accrued liabilities were as follows:


	June 30,		December 31,		March 31,		December 31,
(in thousands)	2021		2020		2022		2021
Construction in progress accruals					$	4,751	$	8,896
Accrued interest						2,234		274
Compensation and related expenses	$	1,407	$	5,395		1,702		4,572
Accrued loss on supply contract						1,423		1,423
Legal settlement		1,250		1,250		938		1,250
Accrued taxes						824		500
Transaction costs and other legal fees		1,563		1,293		500		850
Construction in progress expenditures		0		531
Other		1,681		751		1,670		1,012
Total accrued liabilities	$	5,901	$	9,220	$	14,042	$	18,777

Note 7.8. Income Taxes

Income tax expense for the three months ended March 31, 2022 was a benefit of $0.3 million. Our effective income tax ~~rate was~~rates were 1.09% and 0 for the three ~~and six~~ months ended ~~June 30,~~March 31, 2022 and 2021, ~~and 2020 because we reported taxable losses in each period and continued~~respectively. Our effective tax rate differed from the federal statutory rate of 21% due to ~~provide a full~~our valuation allowance against substantially all of our net deferred tax assets.

In assessing the realizability of deferred income tax assets, we consider whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The ultimate realization of deferred income tax assets is dependent upon the generation of future taxable income during the periods at which time those temporary differences become deductible.

In making valuation allowance determinations, we consider all available evidence, positive and negative, affecting specific deferred tax assets, including the scheduled reversal of deferred income tax liabilities, projected future taxable income, the length of carry-back and carry-forward periods, and tax planning strategies in making this assessment. At March 31, 2022 we continued to maintain a partial valuation allowance against our net deferred tax assets due to the uncertainty surrounding realization of such assets.

Note ~~8. Operating~~9. Leases

~~We reported~~The following table sets forth the allocation of our operating lease ~~costs as follows:~~costs.


	Three Months Ended June 30,					Six Months Ended June 30,					Three Months Ended March 31,
(in thousands)	2021			2020		2021			2020		2022		2021
Cost of revenue	$	83		$	244	$	613		$	460	$	628	$	530
Selling, general and administrative		(91	)		496		(40	)		951		127		51
Research and development		144			129		288			245		132		144
Total operating lease cost	$	136		$	869	$	861		$	1,656	$	887	$	725

~~The table below sets forth the inputs we used in our Black-Scholes models for Private Warrant valuations and the fair values determined.~~

As Of

Three Months Ended

Six Months Ended

As Of

June 30, 2021

June 30, 2021

June 30, 2021

December 31, 2020

Share price of our common stock

$
25.05

$
17.45

-
$
38.33

$
17.45

-
$
44.26

$
23.51

Expected annual dividend yield (1)

0
%

0
%

0
%

0
%
Expected volatility (2)

40
%

40
%

40
%

40.0
%
Risk-free rate of return (3)

0.76
%

0.76
%

0.76
%
-

0.85
%

0.36
%
Expected warrant term (years) (4)

4.50

4.50

-

4.73

4.50

-

4.99

4.99

Fair value determined per warrant

$
15.14

$
8.53

-
$
27.82

$
8.53

-
$
33.65

$
13.81


~~(1)~~	~~We have not paid and do not currently anticipate paying a cash dividend on our common stock.~~
~~(2)~~	We estimated expected volatilities using stock data for select peer public companies over a timeframe similar to the expected term. We selected peer companies using our judgment and as such, expected volatility is a Level 3 input.
~~(3)~~	~~We estimated risk-free rates based on the expected terms using the U.S. Treasury yield curve in effect as of the valuation dates.~~
~~(4)~~	~~The expected warrant terms are equal to the remaining contractual life of the Private Warrants at each measurement date.~~

Note ~~10.~~11. Debt

The components of long-term debt were as follows:

June 30,

December 31,

(in thousands)

2021

2020

2019 Term Loan

$
-

$
27,000

Subordinated Term Loan

10,205

10,171

NMTC notes

21,000

21,000

Paycheck Protection Program loan

0

1,776

Asset Based Lending Agreement

0

0

Vehicle and equipment notes

434

329

Mortgage notes

254

266

Total

$
31,893

$
60,542

Less: Total unamortized debt issuance costs

(1,984
)

(3,955
)
Less: Current cash maturities net of current portion of debt issuance costs

(333
)

(25,201
)
Total long-term debt

$
29,576

$
31,386


	March 31,			December 31,
(in thousands)	2022			2021
3.25% Convertible Senior Notes	$	240,000		$	240,000
New Market Tax Credit Transactions		21,000			21,000
Subordinated Term Loan		10,205			10,205
Vehicle and Equipment Notes		368			407
Mortgage Notes		236			242
Asset-based Lending Arrangement		0			0
Total	$	271,809		$	271,854
Less: Total unamortized debt issuance costs		(10,132	)		(10,563	)
Less: Current maturities of long-term debt		(218	)		(357	)
Total long-term debt	$	261,459		$	260,934

~~2019 Term Loan~~

~~In March 2019, we entered into a credit agreement (“2019 Term Loan”) for a $~~30 ~~million term loan maturing on~~ ~~October 13, 2023. Principal payments were due in quarterly payments of $375,000~~ beginning April 1, 2019 with the outstanding principal balance due at maturity. The 2019 Term Loan was secured by all real and personal property of Danimer Scientific Holdings, LLC (“DSH”) and its subsidiaries. The 2019 Term Loan provided for financial covenants including a maximum capital expenditures limit, leverage ratio and fixed charge coverage ratio, each of which became more restrictive over time.

~~In July 2020, we modified the 2019 Term Loan such that~~ ~~the applicable margin in the interest rate formula (formerly calculated as the greater of (a)~~ ~~2.25% or (b) three month LIBOR, plus~~ ~~4.5%) changed from 4.5% to a five-level tiered amount ranging from 4.5% if the consolidated senior leverage ratio, as defined in the 2019 Term Loan, was less than 1.5, to as high as~~ ~~6.35% if the consolidated senior leverage ratio was greater than 2.25. When the amendment was executed, the applicable margin was 6.35%.~~3.25% Convertible Senior Notes

On ~~January 29,~~December 21, 2021, we ~~voluntarily paid off and terminated our 2019 Term Loan. All related liens and security interests in our assets and guarantees were terminated and released. We settled the 2019 Term Loan for~~issued $~~27.7~~240 million ~~including the outstanding~~ principal amount of $our 3.250% Convertible Senior Notes due ~~27.0~~2026 ~~million, a prepayment fee of $0.5~~ ~~million and $0.2~~ ~~million in accrued unpaid interest. We recognized a loss of $2.6~~ ~~million upon extinguishment due~~(“Notes”), subject to ~~the prepayment and related fees and the write-off of unamortized debt issuance costs.~~

~~Subordinated Term Loan~~

~~In March 2019, we, through a subsidiary, entered into a subordinated second credit agreement~~an indenture (“~~Subordinated Term Loan”) for $~~10 ~~million in term loans consisting of two loans in the amounts of $5.5~~ ~~million and $4.5~~ ~~million with essentially the same terms. The term loans mature on February 13, 2024 and require monthly interest only payments, with the outstanding principal balance due at maturity.~~ ~~The base interest rate is the “Prime Rate” as quoted by the Wall Street Journal (adjusted each calendar quarter;~~ ~~3.25% and~~ ~~3.25% at June 30, 2021 and December 31, 2020, respectively) plus~~ ~~2.75%. We have the option to pay up to two percent (~~2~~%) in any interest payable in any fiscal quarter by adding such interest payment to the principal balance of the related note (“PIK Interest”~~Indenture”).~~During the year ended December 31, 2020, we used the PIK Interest option and an additional $0.2~~ million was included in the principal balance at December 31, 2020. The Subordinated Term Loan provided for financial covenants including a maximum capital expenditures limit, leverage ratio, fixed charge coverage ratio and adjusted EBITDA covenants, certain of which became more restrictive over time.

~~On March 18, 2021, we amended the Subordinated Term Loan to, among other things, change the base rate from the prime rate to LIBOR, lower the applicable margin to~~ 2~~% from 2.75%, remove certain prepayment requirements, convert the financial covenants to “springing” financial covenants that do not apply as long as the subsidiary has at least $~~10 ~~million of unrestricted cash on deposit, increase the capital expenditure covenant, and restrict our ability to prepay the loan until after July 1, 2022.~~

The ~~Subordinated Term Loan remains secured by all real~~Notes are our senior, unsecured obligations and ~~personal property of DSH and its subsidiaries but is subordinated to all other existing lenders. At June 30, 2021, we were in compliance with all financial covenants.~~

~~New Markets Tax Credit Transactions~~

We have entered into financing arrangements under the New Markets Tax Credit (“NMTC”) program with various unrelated third-party financial institutions (individually and collectively referred to as “Investors”) during 2012, 2013 and 2019. The NMTC program was provided for in the Community Renewal Tax Relief Act of 2000 (the “Act”) to induce capital investment in qualified lower income communities. The Act permits taxpayers to claim credits against their federal income taxes for up to 39% of qualified investment in the equity of the community development entities (“CDEs”). CDEs are privately managed investment institutions that are certified to make qualified low-income community investments.

These financing arrangements were structured with the Investors, their wholly owned investment funds (“Investment Funds”) and their wholly owned CDEs in connection with our participation in qualified transactions under the NMTC program. In each of the financing arrangements, we loaned money (in the form of leverage loans) to the Investment Funds and the Investors invested in the Investment Funds. Each Investment Fund then contributed the funds from our loan and the Investor’s investment to a CDE. Each CDE then loaned the contributed funds to a wholly owned subsidiary of the Company.

The Investors are entitled to substantially all of the benefits derived from the tax credits. The NMTC tax credits are subject to recapture for a compliance period of seven years. During the compliance period, we are required to comply with various regulations and contractual provisions that apply to the NMTC arrangements. We do not expect the maximum potential amount of future payments under this indemnification to exceed the face amount of the related debt, net of leverage loans receivable. We believe that the likelihood of a required payment under this indemnification is remote.

~~Paycheck Protection Program Loan~~

~~In April 2020, we received $1.8~~ ~~million under the Paycheck Protection Program (“PPP Loan”). The PPP Loan had a two-year term and bore~~accrue interest at a rate of ~~1.0~~3.250% per ~~annum. Monthly principal~~annum, payable semi-annually in arrears on June 15 and ~~interest payments were deferred~~December 15 of each year, beginning on June 15, 2022. The terms of the Notes are complex and can be found in greater detail in our Annual Report for ~~six months after~~ the ~~date~~year ended December 31, 2021. We will settle conversions by paying or delivering, as applicable, cash, shares of ~~disbursement.~~common stock or a combination of cash and shares, at our election. The ~~promissory note issued~~initial conversion rate, which is subject to change, is approximately $10.79 per share of common stock. If certain liquidity conditions are met, we may redeem the Notes between December 19, 2024, and October 20, 2026. The Notes will mature on December 15, 2026.

Capped Calls

Also in December 2021, in connection with the ~~PPP Loan contained events~~Notes, we purchased capped calls (“Capped Calls”) with certain well-capitalized financial institutions for $35 million. The Capped Calls are call options that permit us, at our option, to require the counterparties to deliver to us shares of ~~default~~our common stock. We may also net-settle the Capped Calls and ~~other provisions customary for a loan~~receive cash instead of ~~this type. On December 11, 2020, we submitted an application for forgiveness~~shares. We have not exercised any of the ~~PPP Loan.~~

~~In connection with~~Capped Calls at March 31, 2022, and the ~~Business Combination, we entered into an escrow agreement with the PPP lender and~~Capped Calls expire on ~~December 29, 2020 we deposited in escrow $1.8~~April 12, 2027 ~~million, which represented the principal, accrued interest, and escrow fee to pay the loan in full. We classified the amounts in escrow as restricted cash at December 31, 2020.~~

~~During the quarter ended June 30, 2021, our PPP Loan was forgiven and we received the escrow balance, net of associated fees, of $1.8~~ ~~million and as a result recognized a gain of $1.8~~ ~~million.~~.

Asset-based Lending Arrangement

On April 29, 2021, we entered into a credit facility (“Credit Agreement”), which we amended December 15, 2021, with Truist Bank that includes a $20.0 million variable interest rate asset-based lending ~~arrangement and a $1.0~~ ~~million capital expenditure line of credit with customary terms and conditions.~~arrangement. The amount of the revolving commitment available for borrowing at any given time is subject to a borrowing base formula that is based upon our qualifying accounts receivable and inventory. Any borrowings are secured by these assets. These arrangements mature on April 29, 2026.

Interest on any borrowings is payable monthly and is calculated, at our election, using either a a base rate (as defined in the Credit Agreement) plus an applicable margin of 1.50% for revolving loans and 1.75% for equipment loans, or a LIBOR market index rate (“LMIR”) (as ~~defined)~~defined in the Credit Agreement) plus an applicable margin of 2.50% for revolving loans and 2.75% for equipment loans. If we maintain a trailing twelve month consolidated fixed charge coverage ratio (as ~~defined)~~defined in the Credit Agreement) of 1.1:1.0 or better and no event of default exists, then the applicable margins for base rate revolving loans and LMIR rate loans are 1.00% and 2.00%, respectively.

The Credit Agreement contains customary affirmative and negative covenants, ~~with certain permitted exceptions, which, among other things:~~



~~require us to deliver financial statements~~ and ~~other information and to provide notice of certain material events,~~



~~contain certain restrictions on the conduct of our business, the management of cash, and the administration of accounts, inventory and equipment,~~



restrict our ability to own, hold and acquire assets; incur debt and liens; to make investments and payments; to effect fundamental corporate changes, to sell assets, and to enter into certain other types of transactions or agreements.

~~After~~after October 29, 2023, ~~or sooner at our election in order to increase availability under the borrowing base formula,~~ we are required to maintain a trailing twelve month consolidated fixed charge coverage ratio of at least 1.1:1.0.

At March 31, 2022, we had 0 borrowings outstanding under the Credit Arrangement and estimated that our total availability under this arrangement was $1.1 million.

Subordinated Term Loan

The Subordinated Term Loan remains secured by all real and personal property of the borrowing subsidiary and its subsidiaries but is subordinated to all other existing lenders. At March 31, 2022, we were in compliance with all financial covenants.

New Markets Tax Credit Transactions

We entered into financing arrangements under the New Markets Tax Credit (“NMTC”) program during 2019 with various unrelated third-party financial institutions (individually and collectively referred to as “Investors”), which then invest in certain "Investment Funds.

In each of the financing arrangements, we loaned money to the Investment Funds. These loans of $13.4 million are recorded as leveraged loan receivables as of March 31, 2022 and December 31, 2021. Each Investment Fund then contributed the funds from our loan and the Investor’s investment to a special purpose entity, which then in turn loaned the contributed funds to a wholly owned subsidiary of the Company.

We believe these borrowings, and our related loans to the Investment Funds, will be forgiven in 2026.

Vehicle and Equipment Notes

We have 17 vehicle and equipment notes outstanding at March 31, 2022 primarily relating to motor vehicles and warehouse equipment. We make monthly payments on these notes at interest rates ranging from 5.11% to 8.49%.

Mortgage Notes

We have 2 mortgage notes secured by residential property. These notes bear interest at 6.5% and 5.25% with maturity dates in October 2023 and March 2025.

Also on April 29, 2021, we entered into a guaranty and security agreement with Truist Bank. Pursuant to this security agreement, we granted a security interest in substantially all of the personal property to secure the obligations under the Credit Agreement and we guaranteed, on an unsecured basis, all of the obligations under the Credit Agreement.12

Note ~~11.~~12. Equity

~~Outstanding Shares~~Common Stock

The following table summarizes the common stock activity for the three ~~and six~~ months ended ~~June 30,~~March 31, 2022 and 2021, ~~and 2020:~~respectively.


	Three Months Ended				Six Months Ended				Three Months Ended March 31,
	June 30,				June 30,				2022			2021
	2021		2020 (1)		2021		2020 (1)
Common stock:
Balance, beginning of period		85,339,145		29,005,309		84,535,640		25,371,186		100,687,820			84,535,640
Issuance of common stock		12,392,934		-		13,196,439		3,634,123		72,395	��		803,505
Balance, end of period		97,732,079		29,005,309		97,732,079		29,005,309		100,760,215			85,339,145

(1) Retroactively restated for Business Combination

Public Warrants

At December 31, 2020, there were ~~10,000,000~~10 million outstanding publicly traded warrants to purchase shares of our common stock with an exercise price of $11.50 per share, subject to adjustments (“Public Warrants”). The Public Warrants were exercisable and potentially redeemable after May 7, 2021.

~~We could redeem the~~On June 16, 2021, we redeemed 50,965 Public Warrants, ~~at a price of $0.01~~ ~~per warrant upon a minimum of 30 days’ prior written notice of redemption, if and only if the last sale price of our common stock equaled or exceeded $18.00~~ ~~per share for any 20-trading days within a 30-trading day period ended three business days before we sent the notice of redemption~~which included all unexercised Public Warrants. Prior to the ~~warrant holders. This requirement was met and on May 14, 2021, we notified holders of the Public Warrants of our intent to redeem them on June 16, 2021. As a result,~~redemption, 12,033,169 Public Warrants, including some Public Warrants that had initially been Private Warrants, were ~~exercised and~~ ~~50,965~~ ~~Public Warrants were redeemed.~~exercised. Net of fees, we collected $~~138.2~~138.1 million in connection with ~~the~~these exercises and redemptions. The Public Warrants had qualified as equity instruments and we had included them in additional paid-in ~~capital at December 31, 2020.~~capital.

Non-Plan Legacy Danimer Options and Warrants

Prior to 2017, Legacy Danimer had issued 208,183 stock options that were not a part of either the 2016 Executive Plan or the 2016 Omnibus Plan. These options had a weighted average exercise price of $30 per share. On December 29, 2020, the then-remaining 30,493 of these options were converted to options to purchase ~~279,253~~279,255 shares of our common stock with a weighted average exercise price of $3.28 per share. During ~~the quarter ended June 30,~~ 2021, 153,763 of these options were ~~exercised.~~exercised and as of March 31, 2022, 125,489 of these options remain.

As of December 29, 2020, Legacy Danimer had ~~55,139~~55,319 warrants outstanding with an exercise price of $30 per share. In connection with the Business Combination, these options were converted to options to purchase 506,611 shares of our common stock with an exercise price of $3.28 per ~~share, and~~share. All remaining Legacy Danimer warrants were exercised during the ~~quarter~~three month period ended March 31, 2021 on a cashless basis by issuing 435,961 ~~shares.~~shares of common stock.

Anti-dilutive Instruments

The following instruments were excluded from the calculation of diluted shares outstanding because the effect of including them would have been anti-dilutive.


	Three Months Ended June 30,				Six Months Ended June 30,				Three Months Ended March 31,
	2021		2020		2021		2020		2022		2021
Convertible debt										22,250,040		0
Employee stock options		37,500		11,108,755		10,682,969		11,108,755		11,227,250		10,682,969
Public Warrants		-		-		-		-		0		10,518,847
Private Warrants		-		-		3,915,863		-		3,914,525		5,481,847
Restricted shares		-		-		3,035,676		-		2,671,482		0
Performance shares										50,251		0
Legacy Danimer options		-		1,906,540		125,490		1,906,540		125,489		279,253
Legacy Danimer warrants		-		506,611		-		506,611
Total excluded instruments		37,500		13,521,906		17,759,998		13,521,906		40,239,037		26,962,916

Note ~~12.~~13. Revenue

We ~~recognize~~evaluate financial performance and make resource allocation decisions based upon the results of our single operating and reportable segment; however, we believe presenting revenue ~~from product~~split between our primary revenue streams of products and services best depicts how the nature, amount, timing and certainty of our net sales and ~~services in accordance with ASC 606,~~ ~~Revenue from Contracts with Customers~~ (“ASC 606”). We derive our revenues primarily from: 1) product sales of developed compostable resins based on polylactic acid (“PLA”), polyhydroxyalkanoates (“PHA”), and other renewable materials; and 2) research and development (“R&D”) services related to developing customized formulations of biodegradable resins based on PHA.cash flows are affected by economic factors.

We generally produce and sell finished products, for which we recognize revenue upon shipment. Due to the highly specialized nature of our products, returns are infrequent, and therefore we do not estimate amounts for sales returns and allowances. There are no forms of variable consideration such as discounts, rebates, or volume discounts that we estimate to reduce our transaction price.

We defer certain contract fulfillment costs. These costs are amortized to cost of revenue on a per-pound basis as we sell the related product. During the three ~~and six~~ months ended ~~June 30,~~March 31, 2022 and 2021, we charged $.$~~0.1~~0.2 million and $~~0.3~~0.2 million, respectively, of fulfillment costs to cost of revenue. At ~~June 30, 2021~~March 31, 2022 and December 31, ~~2020~~2021 we had recorded gross contract assets of $~~2.0~~2.6 million and $~~1.5~~1.4 million, respectively, related to these fulfillment costs.

R&D service revenues generally involve milestone-based contracts under which we work with a customer to develop a PHA-based specific solution designed to the customer’s specifications, which may involve a single or multiple performance obligations. At the inception of ourOur R&D services ~~contracts,~~contract customers generally pay ~~consideration~~us at the commencement of the agreement and then at ~~milestones~~additional intervals as outlined in ~~the contracts.~~each contract. We recognize contract liabilities for such ~~progress with an input method based on personnel hours incurred to date as a percentage of total estimated personnel hours consideration initially,~~payments and then ~~reduce each contract liability by recognizing~~recognize revenue ~~for our R&D services over time by measuring progress for each~~as we satisfy the related performance ~~obligation identified within each contract.~~obligations. To the extent collectible revenue recognized under this method exceeds the consideration received, we recognize contract assets for such unbilled consideration.

The following table shows the significant changes in the R&D contract asset and contract liability ~~balances for~~balances.


	March 31,					December 31,
	2022					2021
(in thousands)	Contract Assets		Contract Liabilities			Contract Assets		Contract Liabilities
Beginning balance	$	2,128	$	(214	)	$	0	$	(2,115	)
Revenue recognized		772		582			2,128		4,157
Unearned consideration received		0		(368	)		0		(2,256	)
Ending balance	$	2,900	$	(0	)	$	2,128	$	(214	)

Disaggregated Revenues

Revenue by geographic areas is based on the ~~six months ended June 30, 2021 and 2020.~~location of the customer. The following is a summary of revenue information by major geographic area:

For the Six Months Ended June 30,

2021

2020

(in thousands)

Contract Asset

Contract Liability

Total Revenue Recognized

Contract Asset

Contract Liability

Total Revenue Recognized

Beginning balance

$
0

$
(2,455
)

$
0

$
(4,580
)

Revenue recognized

1,529

3,251

$
4,780

0

1,256

$
1,256

Unearned consideration received

0

(1,618
)

-

(350
)

Ending balance

$
1,529

$
(822
)

$
4,780

$
0

$
(3,674
)

$
1,256


	Three Months Ended March 31,
(in thousands)	2022		2021
Domestic	$	10,828	$	10,887
Germany		2,689		1,255
Belgium		528		0
Switzerland		301		800
All other countries		397		239
Total revenues	$	14,743	$	13,181

Note ~~13.~~14. Stock-Based Compensation

We grant various forms of stock-based compensation, including restricted stock units, stock options and performance-based restricted stock units under our Danimer Scientific, Inc. 2020 Long-Term Equity ~~Plans~~

~~In connection with the Business Combination, on December 29, 2020, our stockholders approved the~~ Incentive Plan (“2020 Incentive ~~Plan~~Plan”) and ~~the~~employee stock purchase plan instruments under our 2020 Employee Stock Purchase Plan (“2020 ~~ESPP Plan”~~ESPP”).

We also have outstanding employee and director stock options that had been issued prior to the Business Combination under legacy stock plans.

The 2020 Incentive Plan provides for the grant of stock options, stock appreciation rights, and full value awards. Full value awards include restricted stock, restricted stock units, deferred stock units, performance stock and performance stock units. ~~Up to~~

In connection with the acquisition of Novomer, Inc. described in Note 2, we obtained additional authorized share pool of ~~3,093,984~~289,951 shares, which could only be granted to former Novomer, Inc. employees or employees hired after August 11, 2021, of which no shares remain at March 31, 2022.

On January 16, 2022, our Board approved the assumption of the remaining authorized but unissued 2,895,411 shares under the Legacy Danimer 2016 Executive Plan and 2016 Omnibus Plan into our 2020 Incentive Plan.

On March 31, 2022 and December 31, 2021, 1,958,463 shares and 213,997 shares, respectively, of our common stock ~~were~~remained authorized ~~to be issued~~for issuance with respect to awards under the 2020 Incentive Plan. ~~This limit is subject to adjustment in the event of a stock split, stock dividend or other changes in our capitalization.~~

The 2020 ESPP Plan provides for the sale of our common stock to our employees through payroll withholding at a discount of 15% from the lower of the closing price of our common stock on the first or last day of each biannual offering period. Up to 2,571,737 shares of our common stock were authorized to be issued under this plan. ~~The first offering period under the 2020 ESPP Plan commenced on April 1, 2021 and we~~We have issued ~~5,013~~27,407 shares ~~effective June 30, 2021.~~as of March 31, 2022.

These share pool limits are subject to adjustment in the event of a stock split, stock dividend or other changes in our capitalization.

The following table sets forth the allocation of our stock-based compensation expense.


	Three Months Ended March 31,
(in thousands)	2022		2021
Cost of revenue	$	29	$	26
Selling, general and administrative		11,866		5,780
Research and development		1,805		859
Total stock-based compensation	$	13,700	$	6,665

Restricted Shares

OnDuring the three months ended March ~~10,~~31, 2022, we granted 38,659 restricted shares that lapse on February 7, 2023 and 103,092 restricted shares that lapse on successive thirds of the award on February 7, 2023, 2024 and 2025, respectively. We recognize the compensation expense for these shares on a straight-line basis from the grant date through February 7, 2025. During the three months ended March 31, 2021, we ~~completed a Registration Form on Form S-8 to register the shares under the 2020 Equity Incentive Plan and the 2020 ESPP Plan. On this date, a grant of~~granted ~~3,035,676~~1,517,836 ~~shares of~~ restricted ~~stock was effective.~~shares. The restrictions on ~~half~~these shares lapse on successive thirds of the award on December 29, 2021, 2022 and 2023, respectively, and 505,944 of these shares ~~lapse ratably on the first, second, and third anniversaries of the grant date. The fair value of these shares on the date of grant was $37.09~~ ~~and we are recognizing~~vested during 2021. We recognize the compensation expense for these shares on a straight-line basis from the grant date through December 29, 2023. ~~The~~We recognized $4.7 million and $1.4 million of expense related to these awards during the three months ended March 31, 2022 and 2021, respectively, and 1,153,642 shares remained outstanding at March 31, 2022.

Also during the three months ended March 31, 2021, we granted 1,517,840 restricted shares for which the restrictions lapse on successive thirds of the award on the ~~other half~~first date the volume-weighted average price per share of ~~these shares lapse as follows:~~


	1.	~~On the first date the volume-weighted average price per share of~~ our common stock equals or exceeds $~~24.20~~ ~~for any 20 trading dates within a 30-day trading period beginning on December 29, 2021.~~
	2.	~~On the first date the volume-weighted average price per share of our common stock equals or exceeds $24.20~~ ~~for any 20 trading dates within a 30-day trading period beginning on December 29, 2022.~~
	3.	~~On the first date the volume-weighted average price per share of our common stock equals or exceeds $24.20~~ ~~for any 20 trading dates within a 30-day trading period beginning on December 29, 2023.~~

To reflect the effect of this market condition on the vesting of these restricted shares, we valued them using a Monte Carlo simulation, which takes into account a large number of potential stock price scenarios over time and incorporates varied assumptions about volatility and exercise behavior for those various scenarios. A fair value is determined for each potential outcome. The grant date fair value of these restricted shares is the average of the fair values calculated for each potential outcome, or $~~36.57~~24.20. for any 20 trading dates within 30-day trading periods beginning on December 29, 2021, 2022, and 2023, respectively. We are recognizing the compensation expense for these shares on a straight-line basis from the grant date through January 2024. We recognized $4.6 million and $1.4 million of expense during the three months ended March 31, 2022 and 2021, respectively, and all of these shares remained outstanding at March 31, 2022.

~~No other grants~~Performance Shares

On March 31, 2022, we awarded 489,949 shares of restricted stock with performance conditions. These shares are unvested until attainment of performance targets defined in the grant agreement as follows:

•

30% of the shares are subject to a total PHA revenue metric based on 2024 financial results. 50% of these shares vest if total PHA revenue is $151 million, 100% vest if total PHA revenue is $189 million or higher, with prorated vesting between $151 million and $189 million.

•

30% of the shares are subject to an Adjusted EBITDA Metric based on 2024 financial results. 50% of these shares vest if Adjusted EBITDA is $9.2 million, 100% vest if Adjusted EBITDA is $13.8 million or higher, with prorated vesting between $9.2 million and $13.8 million.

•

40% of the shares are subject to a Neat PHA production capacity metric based on a third party assessment at December 31, 2024, 50% of the shares vest if capacity is 68 million pounds, 100% vest if capacity is 81 million pounds or higher, with prorated vesting between 68 million pounds and 81 million pounds.

On July 23, 2021, we awarded 95,943 shares of restricted stock with performance conditions. These shares are unvested until attainment of performance targets defined in the grant agreement as follows:

•

30% of the shares are subject to a return on equity "ROE" metric based on 2023 financial results. 50% of these shares vest if ROE is 5%, 100% vest if ROE is 9% or higher, with prorated vesting between 5% and 9%.

•

30% of the shares are subject to an EBITDA Metric based on 2023 financial results. 50% of these shares vest if EBITDA is $45 million, 100% vest if ROE is $65 million or higher, with prorated vesting between $45 million and $65 million.

•

40% of the shares are subject to a Neat PHA production capacity metric based on a third party assessment at December 31, 2023, 50% of the shares vest if capacity is 75 million pounds, 100% vest if capacity is 90 million pounds or higher, with prorated vesting between 75 million pounds and 90 million pounds.

In addition to these performance conditions, vesting of certain of these shares is also subject to having sufficient capacity in the 2020 Incentive Plan, which may not have ~~been made.~~enough shares remaining to fulfill these awards. In the event registered shares are unavailable, 535,641 of the 585,892 outstanding performance shares must be settled in cash as calculated using the price of our common stock on the vesting date. Due to this cash settlement feature, certain performance shares are accounted for as a liability. During the quarter ended March 31, 2022, we recognized expense of $0.1 million, included in selling, general and administrative expenses, and recorded a long-term liability of $0.1 million. Those certain performance shares are marked to market using the price of our common stock with a life-to-date adjustment. Other than this mark to market effect, expense is recognized on a straight-line basis between the date of grant and the vesting date, which we anticipate will be in February 2024 and March 2025, respectively. All of these performance shares remained outstanding at March 31, 2022.

Stock Options

A summary of stock option activity under our equity plans for the ~~six~~three months ended ~~June 30, 2021~~March 31, 2022 follows:


	Number of Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value		Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Balance, December 31, 2020		11,008,533		$	13.94		8.4	$	105,341,482
Balance, December 31, 2021											10,589,010		$	14.85		7.39	$	22,473,835
Granted		37,500		$	45.41						688,240			3.96
Exercised		(363,064	)	$	3.28			$	15,744,316		(50,000	)		3.28				81,300
Balance, March 31, 2021		10,682,969		$	14.41		8.0	$	249,345,242
Granted		-
Exercised		(200,532	)	$	3.39			$	5,616,689
Balance, June 30, 2021		10,482,437		$	14.62			$	109,293,775

Balance, June 30, 2021:
Balance, March 31, 2022											11,227,250			14.24		7.32		11,642,645
Exercisable		4,791,353		$	4.67	5.9		$	97,647,774		4,357,385		$	4.78		4.96	$	10,334,662
Vested and expected to vest		10,482,437		$	14.62		8.0	$	109,293,775		11,227,250		$	14.24		7.32	$	11,642,645

The aggregate intrinsic values are calculated as the difference between the exercise price of the indicated stock options and the fair value of our common stock on the respective exercise dates or on ~~June 30,~~March 31, 2022, as applicable.

In addition to the stock options granted under our equity plans, during the quarter ended March 31, 2022, we granted 972,222 stock options that contained a cash-settlement feature if adequate shares were not available to settle the award by the vesting dates. During 2021, ~~as applicable.~~we granted 1,710,947 options that vest ratably on the three successive anniversaries of the grant date with the same cash-settlement feature. For the three months ended March 31, 2022, we recognized expense of $0.5 million and recorded a long-term liability of $0.5 million related to these stock options.

The weighted average grant-date fair values of options granted during the ~~quarter~~three month period ended March 31, 2022 and 2021, ~~was~~were $1.77 and $18.52 ~~per option.~~ ~~We have estimated the fair values of our option awards on the date of grant using the Black-Scholes option pricing model with the following assumptions:~~, respectively.


		~~Three and Six Months Ended June 30, 2021~~
~~Expected annual dividend yield~~ ~~(1)~~		~~0.00~~%
~~Expected volatility~~ ~~(2)~~		~~41.50~~%
~~Risk-free rate~~ ~~(3)~~		~~1.05~~%
~~Expected option term (years)~~ ~~(4)~~		6


~~(1)~~	~~We have not paid and do not currently anticipate paying a cash dividend on our common stock.~~
~~(2)~~	~~We estimated the expected volatility using the mean stock price for selected peer public companies over a historic timeframe similar to the expected term.~~
~~(3)~~	~~We estimated the risk-free rate of return using the U.S. Treasury yield curve in effect as of the valuation date.~~
~~(4)~~	~~We estimated the expected term using the “simplified” method described in SEC Staff Accounting Bulletin 14.~~

As of ~~June 30, 2021,~~March 31, 2022, there was $~~143.0~~107.2 million of unrecognized compensation cost related to ~~nonvested~~unvested stock options and restricted shares granted under the 2020 Incentive Plan. That cost is expected to be recognized over a weighted-average period of ~~2.5~~2.9 years.

~~During the quarter ended December 31, 2020, we awarded~~ ~~1,466,874~~ stock options that are contingent upon shareholder approval of an increase in the number of shares issuable under the 2020 Incentive Plan, which has not occurred and which we determined is not a perfunctory exercise, therefore no accounting grant date has been established. As a result, these awards are not reflected in our consolidated financial statements. As described more fully in Note 15, these stock options were modified subsequent to June 30, 2021 and will be treated as liability awards.

Note ~~14.~~15. Commitments and Contingencies

Commitments

In connection with our 2007 acquisition of certain intellectual property, we agreed to pay royalties upon production and sale of PHA. The royalty is $0.05 per pound for the first 500 million pounds of PHA sold and decreases to $0.025 per pound for cumulative sales in excess of that amount until the underlying patents expire. We incurred approximately $0.1 million in royalties during each of the ~~six~~three months ended ~~June 30, 2021~~March 31, 2022 and 2021.

We have open purchase orders related to our Kentucky Facility Phase II expansion and our Greenfield plant construction totaling $125.7 million with anticipated delivery at various dates through August 2024.

In November 2015, we terminated a former executive and terminated our contract with an advisory firm ~~(the “Advisory~~(“Advisory Contract”), pursuant to which we, through the advisory firm, engaged the individual as an executive of the Company. In December 2015, we deemed the Advisory Contract, together with all related arrangements in connection therewith, void, including any share issuances in connection with such arrangements. We filed suit against the former executive and the advisory firm during 2016, and various counterclaims were filed by the former executive and the advisory firm. During the third quarter of 2020, this matter was settled, ~~and~~ we agreed to pay $8$8 million to resolve all outstanding claims, the executive agreed to the cancellation of any shares issued to ~~such executive~~him pursuant to the Advisory Contract and related arrangements, and the ~~exchange~~parties exchanged of mutual ~~releases among the parties.~~releases. The remaining unpaid liability of $0.9 million and $1.25 million is included in accrued liabilities ($~~1.3. million and $1.3~~ ~~million) and other long-term liabilities ($0.6~~ ~~million and $1.3~~ ~~million)~~ at ~~June 30, 2021~~March 31, 2022 and December 31, ~~2020,~~2021, respectively.

Litigation Matters

On May 14, 2021 a class action complaint was filed by Darryl Keith Rosencrants ~~in the United States District Court for the Eastern District of New York, on May 19, 2021 a class action complaint was filed by Elizabeth and John Skistimas~~ in the United States District Court for the Eastern District of New York, on May 18, 2021, a class action complaint was filed by Carlos Caballeros in the United States District Court for the Middle District of Georgia, ~~and~~ on May 18, 2021 a class action complaint was filed by Dennis H. Wilkins also in the United States District Court for the Middle District of ~~Georgia.~~Georgia, and on May 19, 2021, a class action complaint was filed by Elizabeth and John Skistimas in the United States District Court for the Eastern District of New York. Each plaintiff or plaintiffs brought the action individually and on behalf of all others similarly situated against the Company and/or Stephen E. Croskrey, John A. Dowdy, III, John P. Amboian, Richard J. Hendrix, Christy Basco, Philip Gregory Calhoun, Gregory Hunt, Isao Noda and Stuart W. Pratt (collectively, “Defendants”).Company.

The alleged class varies in each case but covers all persons and entities other than Defendants who purchased or otherwise acquired our securities ~~of the Company~~ between October 5, 2020 and May 4, 2021 ~~(the “Class~~(“Class Period”). Plaintiffs are seeking to recover damages caused by Defendants’ alleged violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 ~~Act,~~(“1934 Act”) and Rule 10b-5 promulgated thereunder. The complaints are substantially similar and are each premised upon various allegations that throughout the Class Period, Defendants made materially false and misleading statements regarding, among other things, ~~the Company’s~~our business, operations and compliance policies.

Plaintiffs seek the following remedies: (i) determining that the lawsuits may be maintained as class actions under Rule 23 of the Federal Rules of Civil Procedure, (ii) certifying a class representative, (iii) requiring Defendants to pay damages allegedly sustained by plaintiffs and the class members by reason of the acts alleged in the complaints, and (iv) awarding pre-judgment and post-judgment interest as well as reasonable attorneys’ fees, expert fees and other costs.

On July 29, 2021, the Georgia court transferred the Georgia cases to New York, ~~motions to consolidate are pending~~ and ~~it is expected that~~ all four class actions ~~will be~~have been consolidated into a single lawsuit in the Eastern District of New York. ~~When~~

On January 19, 2022, a ~~consolidated~~Consolidated Amended Class Action Complaint (“Amended Complaint”) was filed in the Eastern District of New York, naming as defendants the Company, its directors and certain of its officers as well as certain former directors (collectively, “Defendants”). The Amended Complaint is brought on behalf of a class consisting of (i) purchasers of shares of the Company during the period October 5, 2020 to May 4, 2021, (ii) all holders of the Company’s Class A common stock entitled to vote on the merger transaction between the Company and Meredian Holdings Group, Inc. consummated on December 28, 2020 and (iii) purchasers of Company securities pursuant to the Company’s Registration Statement on Form S-4 that was declared effective on December 16, 2020 or the Company’s Registration Statement on Form S-1 that was declared effective on February 16, 2021. The Amended Complaint asserts claims for violations of Sections 10(b), 14(a) and 20(a) of the Securities Exchange Act of 1934 and Rules 10(b)-5(a)-(c) promulgated thereunder and Sections 11, 12 and 15 of the Securities Act of 1933. Plaintiffs seek the following remedies: (a) a determination that the lawsuit is a proper class action ~~complaint is filed,~~pursuant to Rule 23 of the Federal Rules of Civil Procedure and certifying Plaintiffs as class representative, (b) awarding compensatory and punitive damages allegedly sustained by the class members by reason of the acts set forth in the Amended Complaint and (c) awarding pre-judgment and post-judgment interest and costs and expenses, including reasonable attorneys’ fees and experts’ fees and other costs. The Defendants ~~intend to make~~will file a motion to ~~dismiss.~~dismiss the Amended Complaint in accordance with the following briefing schedule: motion due by May 13, 2022, opposition due by July 14, 2022 and reply due by August 30, 2022.

On May 24, 2021, a shareholder derivative lawsuit was filed in the Court of Chancery of the State of Delaware by Richard Delman on behalf of the Company, alleging breach of fiduciary duty against the Company’s directors. ~~That~~On October 6, 2021, a shareholders derivative lawsuit ~~has~~was filed in the United States District Court for the District of Delaware by Ryan Perri on behalf of the Company, alleging breach of fiduciary duty against the Company’s directors. Both derivative lawsuits have been stayed pending the outcome of Defendants’ intended motion to dismiss the securities class actions.

~~The above~~ These derivative complaints repeat certain allegations which are already in the public domain. Defendants deny the allegations of the above complaints, believe the lawsuits are without merit and intend to defend them vigorously.

Since we are unable to estimate the ~~amounts~~likelihood of incurring a loss, or the amount of loss, if any, related to these matters, ifwe have not accrued any ~~cannot~~losses for these matters at March 31, 2022.

On May 5, 2021, we received a letter from the Atlanta regional office of the SEC, in connection with a non-public, fact-finding inquiry, requesting that we voluntarily produce certain specified information. On July 14, 2021, we timely and voluntarily produced the information requested by the SEC. On January 26, 2022, we received a follow-up request from the SEC for additional documents and information. By April 8, 2022, we timely and voluntarily produced the additional information requested by the SEC and have since received no further correspondence.

In the ordinary course of business, we may be ~~reasonably estimated at this~~a party to various other legal proceedings from time ~~no amounts have been accrued for this matter at June 30, 2021.~~to time.

Item 2. ~~Management’s Discussion and Analysis of Financial Condition and Results of Operations.~~MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Quarterly Report on Form 10-Q (this “Report”) of Danimer Scientific, Inc. contains ~~forward-looking statements.~~"forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Except where the context otherwise requires or where otherwise indicated, the terms the “Company,” “Danimer,” “we,” “us,” and “our,” refer to the consolidated business of Danimer Scientific, Inc. ~~(formerly known as Live Oak Acquisition Corp.)~~ and its consolidated subsidiaries. All statements in this Report, other than statements of historical fact, are forward-looking statements These forward-looking statements are based on management’s current expectations, assumptions, hopes, beliefs, intentions, and strategies regarding future events and are based on currently available information as to the outcome and timing of future events. Forward-looking statements may contain words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “could,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” the negative of such terms and other similar expressions which are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. The Company cautions you that these forward-looking statements are subject to all of the risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of the Company, incident to its business. Actual results and timing of selected events may differ materially from those anticipated in the forward-looking statements as a result of various factors, including those set forth under the section entitled “Risk Factors” or elsewhere in this Report.

Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. These forward-looking statements are based on information available as of the date of this Report (or, in the case of forward-looking statements incorporated herein by reference, if any, as of the date of the applicable filed document), and any accompanying supplement, and current expectations, forecasts and assumptions, and involve a number of risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing the Company’s views as of any subsequent date, and the Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include:

Any expectations based on these forward-looking statements are subject to risks and uncertainties and other important factors, including those discussed in this Report, specifically the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Other risks and uncertainties are and will be disclosed in our prior and future ~~Securities and Exchange Commission (~~“SEC”). filings. The following information should be read in conjunction with the Condensed Consolidated Financial Statements and related notes appearing in Part I, Item 1 of this Report.

The following discussion and analysis of our financial condition and results of operations describes the business historically operated by Meredian Holdings Group and its subsidiaries (“Legacy Danimer”) under the “Danimer Scientific” name as an independent enterprise prior to December 29, 2020.

On December 29, 2020, the registrant, Live Oak Acquisition Corp. (“Live Oak”), merged with and into Legacy Danimer, with Legacy Danimer surviving as the surviving company (“Business Combination”) and as a wholly owned subsidiary of Live Oak, and changed its name from Live Oak Acquisition Corp. to Danimer Scientific, Inc. (“Danimer”). Live Oak was incorporated in the State of Delaware on May 24, 2019 as a special purpose acquisition company formed for the purpose of effecting a business combination with one or more businesses. Live Oak completed its initial public offering in May 2020.

”) in exchange for $153.9 million in cash, gross of cash acquired, subject to certain customary adjustments as set forth in the merger agreement. Danimer Catalytic Technologies' financial results are included in those of the Company from that date forward. Danimer Catalytic Technologies utilizes feedstocks as an input into its proprietary thermal catalytic conversion process to produce a unique type of PHA or p(3HP) or otherwise referred to under its brand name as Rinnovo.

We are a performance polymer company specializing in bioplastic replacement for traditional petroleum-based plastics. We bring together innovative technologies to deliver ~~renewable, environmentally friendly~~biodegradable bioplastic materials to global consumer product companies. We believe that we are the only commercial company in the bioplastics market to combine the production of a base polymer along with the reactive extrusion capacity in order to give customers a “drop-in” replacement for a wide variety of petroleum-based plastics. We derive our revenue from product sales of PLA- and PHA-based resins as well as from services such as R&D and tolling.

We are a leading producer of polyhydroxyalkanoate (“PHA”), a ~~new, 100%~~ biodegradable plastic ~~feedstock~~ alternative, which we sell under the proprietary Nodax® brand name, for use in a wide variety of plastic applications including ~~water bottles,~~ straws and food containers, among other things. ~~We originally acquired the technology to produce PHA from Procter & Gamble in 2007.~~ We make Nodax through a fermentation process where bacteria consume vegetable oil and make PHA within their cell ~~membranes~~walls as energy reserves. We harvest the PHA from the bacteria, then purify and filter the bioplastic before ~~extruding~~forming the PHA into pellets, which we ~~sell~~combine with other inputs using a reactive extrusion process to ~~converters.~~manufacture formulated finished product. PHAs are a complete replacement for petroleum-based plastics where the convertors do not have to purchase new equipment to switch to the new biodegradable plastic. Utilizing PHA as a base resin significantly expands the number of potential applications for bioplastics in the industry and enables us to produce resin that is not just compostable, but also fully biodegradable.

~~Having successfully scaled up PHA production from the laboratories to a contract manufacturer and later to our own commercial development plant, we~~We recently began making PHA on a commercial scale. In December 2018, we acquired a fermentation facility in Winchester, Kentucky (“Kentucky Facility”). We embarked on a two-phase commissioning strategy for the Kentucky Facility. ~~We commenced scale-up fermentation runs~~Phase II construction is underway with production expected to commence in ~~December 2019 and completed several components~~the second quarter of the Phase I improvements by the end of 2020. Through June 30, 2021, we have invested $57 million for Phase I and related projects, excluding capitalized interest. Once Phase I is producing at full capacity, we expect to produce approximately 20 million pounds of finished product per year. We believe that2022, which will expand the capacity of the plant ~~can be expanded~~ by ~~another~~ 45 million pounds of finished product, bringing total plant capacity up to 65 million pounds of finished product per year, by investing an estimated $114 million (plus or minus 4%) for the Phase II expansion, excluding capitalized interest and internal labor. We have commenced Phase II construction and expect to complete the buildout during the second quarter of 2022.year. We have invested ~~$61.6~~approximately $122 million of the projected $128 million, in the Phase II expansion through ~~June 30,~~March 31, 2022 excluding pre-engineering costs, capitalized interest and internal labor and overhead.

In November 2021, we broke ground for the construction of a PHA plant in Bainbridge, Georgia (“Greenfield Facility”) that would require a capital investment of approximately $500 million to $612 million with a planned annual production capacity of approximately 125 million pounds of finished product. Through March 31, 2022, we have invested approximately $100 million in the Greenfield Facility, excluding capitalized interest and internal ~~labor.~~labor and overhead. We may add additional capacity to the Greenfield Facility at a future date.

We currently anticipate spending between $100 million to $180 million on the Rinnovo plant. Once the Rinnovo plant is completed and after making some additional investments in extrusion capacity, the Danimer network is expected to have production capacity of approximately 330 million pounds of PHA-based finished product resins when blended with other inputs. Danimer also expects to have approximately 60 million pounds of Rinnovo remaining to sell on a standalone basis or in formulations that don't include Nodax.

Since 2004, we have been producing proprietary plastics using a natural plastic called polylactic acid (“PLA”) as a base resin. ~~While PLA is produced by other biopolymer manufacturers,~~ PLA has limited functionality in its unformulated, ~~(“neat”)~~or “neat,” form. We purchase ~~neat~~ PLA and formulate it into bioplastic ~~applications~~resins by leveraging the expertise of our chemists and our proprietary reactive extrusion process. Our formulated PLA products allow many companies to begin to use renewable and compostable plastics to meet their customers’ growing sustainability needs. We were the first company in the world to create a bioplastic suitable for coating disposable paper cups to withstand the temperatures of hot liquids such as coffee. We have expanded our product portfolio and now supply customers globally.

Our technology team partners with global consumer product companies to develop custom biopolymer formulations for specific applications. R&D contracts are designed to develop a formulated resin using PHA, PLA and other biopolymers that can be run efficiently on existing conversion equipment. We expect successful R&D contracts to culminate in supply agreements with the customers. Our R&D services not only provide revenue but also a pipeline of future products.

In addition to producing our own products, we also toll manufacture for customers that need the unique extruder or reactor setup we employ for new or scale-up production. Our specialty tolling services primarily involve processing customer-owned raw materials to assist them in addressing their extrusion capacity constraints or manufacturing challenges.

Our results of operations may not be comparable between periods as a result of the Business Combination ~~with Live Oak.~~and the acquisition of

As a result of the Business Combination, we are an SEC-registered and NYSE-listed company, which will require us to continue to hire additional personnel and implement procedures and processes to address public company regulatory requirements and customary practices. We expect to continue to incur additional expenses as a public company for, among other things, directors’ and officers’ liability insurance, director fees and additional internal and external accounting and legal and administrative resources, including increased audit and legal fees.Danimer Catalytic Technologies

We believe that our performance and future success depend on several factors that present significant opportunities for us but also pose risks and challenges, including those discussed below.

Our product revenue is significantly impacted by our ability to successfully scale the Kentucky Facility for commercial production of PHA. The completion of Phase II of the Kentucky Facility will significantly increase our capacity to produce and sell PHA, which is in high demand by our customers. Using Nodax as a base resin significantly expands the number of potential applications for bioplastics and also enables us to produce a resin that is not just compostable, but also fully biodegradable. Since we just recently introduced our PHA on a commercial scale, our product revenues are also impacted by the timing and success of customer trials as well as product degradation testing and certifications. Our product revenue from PLA-based resins is primarily impacted by the effective launch of new product offerings in new markets by our customers as well as the ability of our suppliers to continue to increase their production capacity of neat PLA. Finally, our product revenue is impacted by our ability to deliver biopolymer formulations that can be efficiently run on customer conversion equipment and meet customer application specifications and requirements. Revenue from product sales is generally recognized when the finished products are shipped to customers. Due to the highly specialized nature of our products, returns are infrequent and we do not offer rebates or volume discounts that would impact selling prices.

Our services revenue is primarily impacted by the timing of, and execution against, customer contracts. Research and development services generally involve milestone-based contracts to develop PHA-based solutions designed to a customer’s specifications and may involve single or multiple performance obligations with the transaction price being allocated to each performance obligation based on the standalone selling prices of the performance obligations.specifications. Service revenues are recognized over time with progress measured based on personnel hours incurred to date as a percentage of total estimated personnel hours for each ~~performance obligation within the~~ contract. Upon the completion of research and development contracts, customers generally have the option to enter into long-term supply agreements with us for the developed product solutions. Our ability to grow our services revenue depends on our ability to develop a track record of developing successful biopolymer formulations for our customers and effectively transitioning those formulations to commercial scale production.

Cost of revenue is comprised of costs of goods sold and direct costs associated with research and development service ~~contracts.~~projects. Costs of goods sold consists of raw materials and ingredients, labor costs including stock-based compensation for production staff, related production overhead, rent and depreciation costs. Costs associated with research and development service contracts include labor costs, related overhead costs and outside consulting and testing fees incurred in direct relation to the specific service ~~contracts.~~contract.

Selling, general and administrative expense consists of ~~labor costs,~~salaries, marketing expense, corporate administration expenses, stock-based compensation not allocated to research and development or ~~production~~costs of revenue personnel, and elements of depreciation, rent and facility expenses that are not directly attributable to direct costs of production or associated with research and development activities.

Research and development expense includes ~~labor costs,~~salaries, stock-based compensation, third-party consulting and testing fees, and rent and related facility expenses directly attributable to research and development activities not associated with revenue generating service ~~contracts.~~projects.

In March 2020, the World Health Organization declared the outbreak of COVID-19 to be a global pandemic and recommended containment and mitigation measures worldwide. In response, government authorities have issued an evolving set of mandates, including requirements to shelter-in-place, curtail business operations, restrict travel and avoid physical interaction. These mandates and the continued spread of COVID-19 have disrupted normal business activities in many segments of the global economy, resulting in weakened economic conditions. Government mandates have been lifted by certain public authorities and economic conditions have improved in certain sectors of the economy. Certain regions of the world have experienced increasing numbers of COVID-19 cases, however, and if this continues and if public authorities intensify efforts to contain the spread of COVID-19, normal business activity may be further disrupted and economic conditions could weaken.

Our ability to continue to operate without any significant negative impacts will in part depend on our ability to protect our employees and our supply chain. We have endeavored to follow actions recommended by governments and health authorities to protect our employees, with particular measures in place for those working in our manufacturing and laboratory facilities. We have been able to broadly maintain our operations, and we intend to continue to work with our stakeholders (including customers, employees, suppliers and local communities) to responsibly address this global pandemic. However, uncertainty resulting from the global pandemic could result in an unforeseen disruption to our supply chain (for example a closure of a key manufacturing or distribution facility or the inability of a key ~~material~~supplier or transportation ~~supplier~~partner to source and transport ~~materials)~~materials and equipment) that could impact our ~~operations.~~operations and capital projects.

Although our revenue has continued to grow during the continuing global pandemic, we believe that some of our customers have deferred decision making and commitments regarding future orders and new contracts. The global pandemic has also resulted in delays in performing trials with new customers and obtaining certification for new products. During this period and especially prior to the Business Combination, we have delayed certain capital expenditures in order to conserve financial resources, resulting in a slower than expected scale up of the Kentucky Facility. We have not observed any material impairments of, ~~our assets~~ or aother significant ~~change in~~changes to, the fair value of our assets due to the COVID-19 pandemic.

For additional information on risk factors that could impact our results, please refer to “Risk Factors” located elsewhere in this Report.

During the ~~second~~first quarter, we made further inroads in our mission to create biodegradable consumer packaging and other products which address the global plastics waste crisis, building on our team’s many accomplishments since we became a public company ~~just over seven months ago. In the second quarter alone:~~in late 2020 by:

In August 2021, we closed on the acquisition of Novomer, Inc., a leading developer of conversion technology providing transformable, functional and low net carbon inputs into the production of PHA-based resinsU.S. and other ~~biodegradable materials,~~governments.

While we do not have operations in either country, we have experienced a cash transaction valued at $152 million, subject to customary adjustments. Novomer develops high-performing, carbon-efficient, cost-effective polymers and chemicals, including poly(3-hydroxypropionate) (“p(3HP)”), a type of PHA under its brand name, Rinnovo. We believe that Novomer’s technology will enhance the strength of product applications we developdecline in sales due to the ~~complementary nature~~conflict. We have also experienced supply chain challenges and increased logistics and raw material costs which we believe may be due in part to the negative impact on the global economy from the ongoing war in Ukraine, including but not limited to canola oil, which our PHA production currently uses as a feedstock. Prior to the Russian invasion, Ukraine was a significant producer of ~~Novomer’s polymers when combined with Nodax~~canola, though we do not source from Ukraine, and ~~enable us~~we have already placed orders to ~~increase the expected overall volume of finished product we will be able~~reduce our exposure to ~~deliver, all while significantly lowering our production costs and capital expenditure per pound produced.~~shortages or inflation.

~~To meet~~The extent to which the ~~growing demand for our resins, we regularly evaluate our manufacturing capacity~~conflict may continue to ~~pursue~~impact Danimer in future periods will depend on future developments, including the ~~most effective~~severity and ~~efficient way~~duration of the conflict, its impact on regional and global economic conditions, and the extent of supply chain disruptions. We will continue to produce materials. In March 2021, we announced our plan to construct a greenfield PHA plant in Bainbridge, Georgia, that would require a capital investment of approximately $700 million with a planned annual production capacity of approximately 250 million pounds of finished product. In July, we received an updated engineering estimated formonitor the ~~greenfield plant of $826 million (+/- 25%) based on continued inflation in construction materials throughout 2021. Considering~~conflict and assess the recent acquisition of Novomer, we have modified our plans to include Novomer’s expansion through the construction of a commercial Rinnovo plant. In turn, we are modifying the plans for our Bainbridge greenfield facility to include three fermenters in the near term, compared to the six fermenters that we had previously stated, while retaining the same amount of extrusion capacity included in the initial plan. Based on this updated three-fermenter design, we’ve updated our engineering estimate for the Bainbridge greenfield plant to $493 million (+/- 25%). We currently anticipate spending between $100 million to $180 million on the Rinnovo plant. We anticipate producing at least as much finished product as previously planned by incorporating Rinnovo into our finished products while maintaining the extrusion capacity contemplated in the original greenfield development plan. The Company anticipates adding the additional fermentationrelated sanctions and ~~downstream processing models to the greenfield at a future date.~~other effects and may take further actions if necessary.

The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of revenue and expenses during the reported periods. ~~The more critical accounting estimates include estimates related to revenue recognition, stock-based compensation, leases and derivatives. We also have other~~Our disclosure of our key accounting policies, which involve the use of estimates, judgments and assumptions that are significant to understanding our results, ~~which~~ are set forth in our Annual Report on Form ~~10-K/A~~10-K for the year ended December 31, ~~2020.~~2021.

Condensed Consolidated Results of Operations for the Three Months Ended March 31, 2022 and 2021:

~~We recognize~~The increase in product revenue ~~from~~was driven by a 15% increase in pounds sold and a 4% increase in our weighted average selling price. In the first quarter of 2022, PHA-based products represented 52% of total revenue and only represented 29% of total revenue during the same period in the prior year. PHA-based product sales ~~and services~~increased $3.9 million due to production capacity ramp-up in ~~accordance with Financial Accounting Standards Board ASC (“ASC”)Topic 606,~~ ~~Revenue from Contracts with Customers~~.our Kentucky Facility. PLA-based product sales decreased $1.8 million compared to the prior year period primarily due to the conflict in Ukraine.

~~We derive our revenues from: 1) product sales of developed compostable resins based on PLA, PHA, and other renewable materials; and 2)~~The decrease in service revenue relates primarily to a $0.6 million decrease in revenue from research and development ~~(R&D) services related to developing customized formulations of biodegradable resins based on PHA, PLA and other biopolymers as well as tolling revenues.~~

We generally produce and sell resin pellets, for which we typically recognize revenue upon shipment. Due to the highly specialized nature of our products, returns are infrequent, and therefore we do not estimate amounts for sales returns and allowances. We offer a standard quality assurance warranty related to the fitness of our finished goods. There are no forms of variable consideration such as rebates or volume discounts.

R&D service revenues generally involve milestone-based contracts under which we work with a customer to develop a PHA-based solution designed to the customer’s specifications, which may involve a single or multiple performance obligations. When an R&D contract has multiple performance obligations, we allocate the transaction price to the performance obligations utilizing a cost-plus approach to estimate the stand-alone selling price, which contemplates the level of effort to satisfy the performance obligations, and then allocate the transaction price to each of the performance obligations based on the relative percentage of the stand-alone selling price.contracts. We recognize revenue for these R&D services over time with progress measured ~~utilizing an input method~~ based on personnel hours incurred to date as a percentage of total estimated personnel hours for each performance obligation identified within the contract. Upon completion of the R&D services, the customers have an option to enter into long-term supply agreements with us for the product(s) that were developed within the respective contracts. We concluded these customer options were marketing offers, not separate performance obligations, since the options did not provide a material right to any of our customers.

~~We have granted stock options~~contract, and restricted shares to our employees with either service-based conditions only or market-based and service-based conditions that affect vesting. We recognize expense for these awards based on their grant date fair values on a straight-line basis over the requisite service period, or,we incurred fewer such hours in the case of awards with both market-based and service-based vesting conditions, over the longest of the explicit, implicit or derived service period of the award. We determine grant date fair values using a Black-Scholes option pricing model for service-based only option awards and a Monte Carlo simulation for market-based and service-based awards.current year as certain projects near completion.

~~We account for leases in accordance with ASC 842,~~ ~~Leases~~ and we determine if an arrangement is a lease at inception. We use our incremental borrowing rate based on the information available at lease commencement dates, such as rates recently offered to us by lenders on proposed borrowings, in determining the present values of future payments. Our incremental borrowing rate for a lease is the rate of interest we would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. Our lease terms may include options to extend or terminate the lease, typically at our own discretion. We evaluate the renewal options at commencement and if they are reasonably certain of exercise, we include the renewal period in the lease term.

Lease costs associated with operating leases consist of both fixed and variable components. Expenses related to fixed lease payments are recognized on a straight-line basis over the lease term. Variable payments, such as insurance and property taxes, are recorded as incurred and are not included in the initial lease liability.

~~We account for outstanding privately-held warrants to purchase our common stock for $11.50 per share as derivatives under ASC 815,~~ ~~Derivatives and Hedging~~ ~~and therefore we report these warrants as a liability at their fair value and report mark-to-market changes in their fair value in current income.~~

~~Condensed Consolidated Results of Operations for the~~ Three ~~Months Ended June 30, 2021 and 2020:~~

The increase in product revenue was driven by an approximately 8% increase in our weighted average selling price, which was partially offset by a 2% decrease in pounds sold. In the second quarter of 2021, PHA-based products represented 29% of our total revenue compared to only 7% during the same period in the prior year. PHA-based product sales increased $3.3 million due to production capacity ramp-up in our Kentucky Facility. PLA-based product sales decreased $2.6 million primarily due to some of our PLA customers deciding to increase their inventory levels in 2020 to protect against potential supply chain disruptions that might have arisen due to the spread of the COVID-19 virus. Once their higher inventory levels were achieved in late 2020, certain of these customers slowed their orders for the first half of 2021.

The increase in services revenue relates primarily to a $1.8 million increase in revenue from research and development contracts, which was driven primarily by signing additional partners to research and development contracts since the end of the prior year period.

~~We have four customers that~~ accounted for ~~53%~~58% and 54% of ~~the~~ total revenue for the three months ended ~~June 30,~~March 31, 2022 and 2021, ~~which compares with three customers that accounted for 64% of the total revenue during the three months ended June 30, 2020.~~respectively.

Cost of revenue increased ~~48%~~37% for the three months ended ~~June 30, 2021~~March 31, 2022 as compared with the three months ended ~~June 30, 2020. The~~March 31, 2021. This is largely driven by the 15% increase in ~~cost~~pounds sold noted above. Cost of revenue ~~is primarily~~for the current quarter includes a ~~result~~$1.0 million charge for inventory associated with certain customers that sell product in Ukraine and a charge for unusual manufacturing costs of $0.3 million resulting from temporary changes put in place during a safety review performed following the ~~cost of PHA-based products representing a significantly larger portion of our total revenue during the second quarter of~~December 2021 ~~compared to the second quarter of 2020, as described above. The average cost per pound of PHA-based products sold~~fire in the quarter was significantly higher than our PLA-based products due to elevated fixed-cost absorption at our Kentucky Facility. Included in the increase in cost of revenue was a $1.2 million increase in depreciation expense primarily relating to our Kentucky Facility, which combined represent another 11% of this increase. Most of the remaining increase is related to the relative mix between PHA and PLA sales. As noted above, PHA sales increased significantly as wea percentage of total product revenue this quarter as compared with the prior year quarter. While the Phase I Kentucky Facility has reached the ability to produce at full capacity, much of what was sold during the quarter had been produced previously, during periods of lower utilization and higher fixed cost absorption rates. As a result, the margin profile of the PHA sold continues to be lower than that of our PLA products. We believe the margin profile of our PHA products will continue to ~~place production assets in service. The average cost per pound~~improve after this older, higher-cost inventory works through the channel and Phase II of ~~PHA-based products sold in the second quarter of 2021 was significantly higher than~~ our ~~PLA-based products due~~expansion comes online and begins to ~~elevated fixed-cost absorption~~operate at ~~our Kentucky Facility. Gross margin percentage decreased to 14% for the three months ended June 30, 2021 from 29% for the three months ended June 30, 2020.~~ scale.

The decline in ~~our~~ gross profit ~~margin~~percentage was primarily due to lower volumes of PLA products that led to a lower margin for those products in the ~~result~~current quarter, combined with lower R&D and tolling services revenue, partially offset by higher PHA volumes at improved margins. Our gross profit percentage was also impacted by $1.3 million, or 9% of ~~these fixed costs at~~total revenue, of specifically-identified charges also noted above for the ~~Kentucky Facility. We anticipate that fixed costs, including rent and depreciation, will become a smaller portion of our cost of revenue as we scale up production.~~

In the second quarter of 2021, we completed the debottlenecking of the Kentucky Facility and expect that these efforts will allow us to significantly scale production from previous levels, further reducing manufacturing costs of PHA-based resins on a per pound basis. We believe this positions us to accelerate production of PHA-based resins towards reaching 100% of the facility's current annual run rate capacity of 20 million pounds by the end of 2021.quarter.

The increase in selling, general and administrative expense was due primarily to an increase in stock-based compensation expense of ~~$12.2~~$6.1 million primarily related to equity awards ~~that were~~ granted since the prior year period as well as $1.5 million in ~~conjunction with~~compensation and benefit related expenses due to headcount increases during the ~~Business Combination,~~prior and current year, an increase of ~~$1.6~~$1.4 million in legal costs incurred to support our transition to becoming a publicly traded company, ~~as well as to defend against ongoing litigation, a $0.5~~$0.6 million increase in office expenses and $0.4 million increase in property and other insurance costs and increased accrued property taxes associated with our growing asset ~~base, and increased compensation and benefits related to hiring additional finance and administrative staff.~~base. The increase in research and development expense period over period was primarily due to $2.6 million increase of R&D expense of Danimer Catalytic Technologies (including $1.7 million of depreciation and amortization), an increase ~~in stock-based compensation expense~~ of ~~$1.7~~$1.0 million ~~primarily related~~due to ~~equity awards that were granted in conjunction with the Business Combination and increased~~ compensation and benefits costs related to additional headcount in the research and development ~~areas.~~areas and an increase in stock-based compensation of $0.9 million primarily related to equity awards granted since the prior year.

The current quarter remeasurement gain on our Private Warrants represents a decrease in the fair value of each of the 3.9 million outstanding Private Warrants due primarily to a decrease in the market price of our common stock during the ~~three months ended June 30, 2021.~~period. The prior year quarter remeasurement loss was, conversely, due to the common stock price increase during that period.

The ~~decrease~~increase in interest expense, net of capitalization, primarily resulted from the ~~payoff the 2019 Term Loan~~issuance of our $240 million principal amount 3.250% Convertible Senior Notes in January 2021, the settlement of convertible notes into equity in the fourth quarter of 2020, and the extinguishment of certain loans issued in connection with the New Markets Tax Credit program. This decrease was offset by capitalized interest, associated primarily with capital expenditures at our Kentucky Facility, declining to $0.1 million for the three months ended June 30, 2021 from $1.1 million for the three months ended June 30, 2020. Interest capitalization declined despite continued capital investment due to lower debt levels.

On April 12, 2021, we received notice that our Paycheck Protection Plan Loan had been forgiven by the Small Business Administration. As a result, we recognized a $1.8 million gain on forgiveness of debt and collected this amount from escrow during the quarter ended June 30,December 2021.

For the ~~three months ended June 30, 2021 and 2020,~~current quarter, we had a tax benefit of $0.3 million as compared to no ~~income~~ tax benefit or expense ~~or benefit.~~in the prior year quarter. Our effective tax rate differed from the federal statutory rate of 21% due to our taxable loss position and maintaining a full valuation allowance. At June 30, 2021, we continued to maintain a full valuation allowance against our net deferred tax assets due to the uncertainty surrounding realization of such assets.

The change in net income (loss) in 2021 compared with 2020 was primarily attributable to the gain on remeasurement of private warrants, partially offset by the increase in operating expenses as discussed in the sections above.

~~Condensed Consolidated Results of Operations for the six months ended June 30, 2021 and 2020:~~

In the first six months of 2021, PHA-based products represented 29% of our total revenue compared to only 5% during the same period in the prior year. Driving this increase in product revenue was a 3% increase in pounds sold and an approximately 9% increase in our weighted average selling price. The $2.6 million increase in product revenue was primarily attributable to increases in PHA-based product sales of $6.9 million offset by a decrease in PLA-based product sales of $4.2 million. The increase in PHA-based product sales was the result of the continued increase of production capacity at our Kentucky Facility. The decrease in PLA-based product sales was primarily the result of some of our PLA customers deciding to increase their inventory levels in 2020 to protect against potential supply chain disruptions that might have arisen due to the spread of the COVID-19 virus. Once their higher inventory levels were achieved in late 2020, certain of these customers slowed their orders in early 2021.

The increase in services revenue relates primarily to a $2.6 million increase in revenue from research and development contracts. We have four customers that accounted for 57% of the total revenue for the six months ended June 30, 2021, which compares with three customers that accounted for 60% of the total revenue during the six months ended June 30, 2020.

Cost of revenue for the six months ended June 30, 2021 increased 52% as compared with the six months ended June 30, 2020. The increase in cost of revenue is primarily a result of the cost of PHA-based products representing a significantly larger portion of our total cost of revenue during the 2021 year to date period compared to the 2020 year to date period. The average cost per pound of PHA-based products sold in the first year to date period of 2021 was significantly higher than our PLA-based products due to elevated fixed-cost absorption at our Kentucky Facility. We expect our average cost per unit sold to improve as the Kentucky Facility continues to scale up production. Included in the increase in cost of revenue was a $2.4 million increase in depreciation expense and a $0.2 million increase in rent expense primarily related to having completed the installation of certain assets at the Kentucky Facility and commencing production. We anticipate that rent and depreciation will become a smaller portion of our cost of revenue as we continue to scale up PHA production at the Kentucky Facility. Gross margin percentage decreased to 13% for the six months ended June 30, 2021 from 29% for the six months ended June 30, 2020. The decline in our gross profit margin was primarily the result of commencing limited PHA manufacturing activities in early 2020 at the Kentucky Facility and the incurrence of associated incremental ramp-up costs, including increased depreciation expense. In the second quarter of 2021, we completed the debottlenecking of the Kentucky Facility and expect that these efforts will allow us to significantly scale production from previous levels, further reducing manufacturing costs of PHA based resins on a per pound basis. We believe the debottlenecking also positions us to accelerate production of PHA-based resins towards reaching 100% of the facility’s current annual run rate capacity of 20 million pounds of PHA-based resins by the end of 2021.

The increase in selling, general and administrative expense was due primarily to an increase in stock-based compensation expense of $17.9 million primarily related to equity awards that were granted in conjunction with the Business Combination, an increase of $1.7 million in legal fees incurred to support our transition to becoming a publicly-traded company as well as to defend against ongoing litigation, an increase of $1.0 million in accounting and auditing fees representing costs incurred to address the financial reporting requirements of becoming a public company, a $0.9 million increase in property and other insurance costs and increased accrued property taxes associated with our growing asset base, and increases in compensation and benefits related to hiring additional finance and administrative staff. The increase in research and development expense period over period was primarily attributed to increases in stock-based compensation expense of $2.5 million primarily related to equity awards that were granted in conjunction with the Business Combination and increased compensation and benefits costs of $0.8 million related to additional headcount in the research and development areas.

The loss on our Private Warrants represents an increase in the fair value of each of the 3.9 million outstanding Private Warrants due primarily to an increase in the market price of our common stock during the six months ended June 30, 2021.

Interest expense decreased primarily due to the payoff of the 2019 Term Loan in January 2021, the settlement of convertible notes into equity in the fourth year to date period of 2020, and the extinguishment of certain loans issued in connection with the New Market Tax Credit program. This decrease was partially offset by capitalized interest declining to $0.3 million for the six months ended June 30, 2021 from $1.8 million for the six months ended June 30, 2020. The interest capitalization primarily relates to the purchase, modification and installation of machinery and equipment at the Kentucky Facility.

During the year to date period ended June 30, 2021, we voluntarily paid off our 2019 Term Loan balance of $27.0 million. We recognized a loss of $2.6 million upon this extinguishment due to the write-off of unamortized debt issuance costs and prepayment and other fees.

On April 12, 2021, we received notice that our PPP Loan had been forgiven by the Small Business Administration. As a result we have recognized a $1.8 million gain on forgiveness of debt, representing principal and interest earned on the balance in escrow, and net of associated fees. This amount was released from escrow during the quarter ended June 30, 2021.

~~For the six months ended June 30, 2021 and 2020, we had no income tax expense or benefit. Our effective tax rate~~rates differed from the federal statutory rate of 21% due to our net loss position and maintaining a full valuation ~~allowance. At June 30, 2021, we continued to maintain a full valuation~~ allowance, ~~against our net deferred tax assets due to~~other than as noted in connection with the ~~uncertainty surrounding realization~~acquisition of ~~such assets.~~ Danimer Catalytic Technologies.

~~The increase in~~We reported a net loss in the three months ended March 31, 2022 of $26.4 million as compared with a loss of $94.7 million in the prior year period. The decrease in loss before income taxes for the three months ended March 31, 2022 compared with 2021 was primarily attributable to ~~the increase in operating expenses and the~~ loss on remeasurement of private warrants during the prior year quarter and a gain on such remeasurement in the current year period. This decrease was offset by increases in operating expenses during the current quarter, as discussed in the sections above.

Our primary sources of liquidity are currently equity issuances and debt financings. ~~We had accumulated deficit of $114.3 million and $58.8 million as of June 30, 2021 and December 31, 2020, respectively.~~ As of ~~June 30, 2021,~~March 31, 2022 we had ~~$416.4~~$210.0 million in cash and cash ~~equivalents and working capital of $422.7 million.~~equivalents. While we believe we have established ~~an ongoing~~a growing source of revenue that will be sufficient to cover our ongoing operating costs once our production reaches scale, we are currently experiencing a period of significant capital expenditures resulting from the ongoing expansion and construction of our manufacturing and production facilities.

Excluding pre-engineering costs, capitalized interest and internal labor and overhead, we have invested $122.3 million in the Phase II expansion through March 31, 2022. In total, we expect to invest $128 million in the Kentucky Facility by the time it is completed. We broke ground on our Greenfield Facility construction ahead of schedule in November 2021 and started placing orders for long-lead time equipment items to mitigate the impacts of ongoing inflation and delivery delays that may result from global supply chain challenges. As of March 31, 2022, we have invested $100 million of capital for the Greenfield Facility, excluding capitalized interest, internal labor and overhead. The completion of the Greenfield Facility is contingent upon receiving additional financing. We believe we have adequate liquidity to fund our operations for the next twelve months.

~~At June 30, 2021,~~We have open purchase orders related to our Kentucky Facility Phase II expansion and our Greenfield plant construction totaling $125.7 million with anticipated delivery at various dates through August 2024.

As of March 31, 2022, our most significant borrowing facilities are our 3.25% Convertible Senior Notes and our Subordinated Term Loan ~~and Asset-based Lending Arrangement~~ described below.

On December 21, 2021, we issued $240 million principal amount of our 3.250% Convertible Senior Notes due 2026 (“Notes”), subject to an indenture (“Indenture”).

The Notes are our senior, unsecured obligations and accrue interest at a rate of 3.250% per annum, payable semi-annually in arrears on June 15 and December 15 of each year, beginning on June 15, 2022. The terms of the Notes are complex and can be found in greater detail in our Annual Report for the year ended December 31, 2021. We will settle conversions by paying or delivering, as applicable, cash, shares of common stock or a combination of cash and shares, at our election. The initial conversion rate, which is subject to change,

is approximately $10.79 per share of common stock. If certain liquidity conditions are met, we may redeem the Notes between December 19, 2024, and October 20, 2026. The Notes will mature on December 15, 2026.

Also in December 2021, in connection with the Notes, we purchased capped calls (“Capped Calls”) with certain well-capitalized financial institutions for $35 million. The Capped Calls are call options that permit us, at our option, to require the counterparties to deliver to us shares of our common stock. We may also net-settle the Capped Calls and receive cash instead of shares. We have not exercised any of the Capped Calls at March 31, 2022, and the Capped Calls expire on April 12, 2027.

In March 2019, we, through a subsidiary, entered into a subordinated second credit agreement (“Subordinated Term Loan”) for $10 million in term loans. The term loans mature on February 13, 2024 and require monthly interest only payments, with the outstanding principal balance due at maturity. ~~After an amendment on March 18, 2021, the base interest rate is the LIBOR (adjusted each calendar quarter; 3.25% and 3.25% at June 30, 2021 and December 31, 2020 respectively) plus 2%.~~ The Subordinated Term Loan provides for “springing” financial covenants including a maximum capital expenditures limit, leverage ratio, fixed charge coverage ratio and adjusted EBITDA covenants, ~~that~~certain of which became more restrictive over time, and which do not apply ~~only if DSH has less than $10 million of~~as long as the borrowing subsidiary maintains an unrestricted cash ~~on deposits and imposes a maximum capital expenditures limit. Our ability to prepay the loan is restricted until after July 1, 2022.~~deposit of at least $10 million.

~~On April 29, 2021,~~The Subordinated Term Loan remains secured by all real and personal property of the borrowing subsidiary and its subsidiaries but is subordinated to all other existing lenders. At March 31, 2022, we ~~entered into a credit facility~~were in compliance with Truist Bank that includes a $20.0 million variable interest rate asset-based lending arrangement and a $1.0 million capital expenditure line of credit with customary terms and conditions. These arrangements mature on April 29, 2026. Interest on any borrowings is payable monthly and is calculated, at our election, using either a base rate (as defined in the Credit Agreement) plus an applicable margin of 1.50% for revolving loans and 1.75% for equipment loans, or a LIBOR market index rate (“LMIR”) (as defined) plus an applicable margin of 2.50% for revolving loans and 2.75% for equipment loans. If we maintain a trailing twelve month consolidated fixed charge coverage ratio (as defined) of 1.1:1.0 or better and no event of default exists, then the applicable margins for base rate revolving loans and LMIR rate loans are 1.00% and 2.00%, respectively. all financial covenants.

Cash ~~flows~~Flows for the ~~six months ended June 30, 2021~~Three Months Ended March 31, 2022 and ~~2020~~2021:

The following table summarizes our cash flows from operating, investing and financing activities:

Net cash used in operating activities was ~~$22.6~~$17.6 million during the ~~six months ended June 30, 2021~~current quarter and was ~~$10.4~~$14.2 million during the comparable period for ~~2020.~~2021. The period-to-period change was primarily attributable to additional personnel-related expenditures associated with headcount increases building our capabilities to operate as a public company and for operating expenses in our Kentucky Facility as well as a $3.2 million increase in cash used to fund changes in working capital.

~~For~~In the ~~six months ended June 30, 2021,~~current quarter, we used ~~$51.9~~$58.9 million for the purchase of property, plant and equipment which ~~compares to $19.1~~exceeds the $23.9 million for such purchases in the ~~purchase of property, plant and equipment for six months ended June 30, 2020.~~prior year quarter. During ~~2021,~~2022, we ~~commenced a further expansion~~continued construction of the ~~production capacity~~Greenfield Facility and Phase II of our expansion of our Kentucky ~~Facility (Phase II). Through June 30, 2021, we have invested approximately $61.6 million, excluding capitalized interest for the Phase II expansion project.~~Facility.

For the ~~six months ended June 30, 2021, net cash provided by financing activities was $111.2 million which consisted of:~~

~~This compares to~~current quarter, net cash provided by financing activities of ~~$28.2~~$0.1 million ~~for~~consisted primarily of:

In the prior year quarter, net cash used in financing activities of $26.6 million consisted primarily of:

At ~~June 30, 2021,~~March 31, 2022, we do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors. The term “off-balance sheet arrangement” generally means any transaction, agreement, or other contractual arrangement to which an unconsolidated entity is a party, under which we have any obligation arising under a guarantee contract, derivative instrument, or variable interest or a retained or contingent interest in assets transferred to such entity or similar arrangement that serves as credit, liquidity, or market risk support for such assets.

We are an emerging growth company (“EGC”), as defined in the JOBS Act, which currently exempts us from the requirement to receive an auditor's report over our internal controls over financial reporting in our Annual Reports on Form 10-K as well as from certain disclosures in our Definitive Proxy Statements on Form DEF14A.

Since the market value of our outstanding securities held by non-affiliates on June 30, 2021 exceeded $700 million, we expect to be deemed a “large accelerated filer,” as defined by the SEC, on January 1, 2022. As a result, our Form 10-K for the year ending December 31, 2021 will be subject to auditor attestation over our internal controls over financial reporting as required by Section 404(b) of the Sarbanes-Oxley Act. Compliance with Section 404(b) will require a significant amount of management's time, and we plan to make material expenditures on information technology, process improvement, headcount additions, and consulting expense in order to comply by the end of this year. There can be no assurance that we will succeed in these efforts, and if we do not, the disclosure of one or more material weaknesses is possible. In such a case, the market value of our common stock could be negatively affected.

~~As a large accelerated filer, we will also have to file a more expansive Definitive Proxy Statement on Form DEF14A, which will require additional time and expense as well.~~

~~As a smaller reporting company,~~We are exposed to various market risks, including potential losses arising from adverse changes in market prices and rates, such as ~~defined~~various commodity prices. We do not enter into derivatives or other financial instruments for trading or speculative purposes.

Our primary financial instruments are cash and cash equivalents. This includes cash in ~~Rule 12b-2 under 1934 Act, as amended, for this reporting period, we~~banks and highly rated, liquid money market investments. We believe these instruments are not ~~required~~subject to ~~provide~~material potential near-term losses in future earnings from reasonably possible near-term changes in market rates or prices.

Our products are made using various purchased components and several basic raw materials, in particular PLA, polybutylene succinate (“PBS”), polybutylene adipate terephthalate (“PBAT”) and canola oil. We expect prices for these items to fluctuate based on marketplace demand and other factors, such as the ~~information required under this item.~~effect of the Russian invasion of Ukraine on canola oil prices. Our product margins and level of profitability may fluctuate whether or not we pass increases in purchased component and raw material costs on to our customers.

Our management, including the Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls can prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. There are inherent limitations in all control systems, including the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of one or more persons. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and, while our disclosure controls and procedures are designed to be effective under circumstances where they should reasonably be expected to operate effectively, there can be no assurance that any design will succeed in achieving its stated goals under all potential conditions. Because of the inherent limitations in any control system, misstatements due to error or fraud may occur and not be detected.

~~Our~~On August 11, 2021, we completed the acquisition of Danimer Catalytic Technologies. SEC guidance permits management ~~with~~to exclude acquisitions from their assessment of internal control over financial reporting during the ~~participation~~first year of an acquisition. In conducting our ~~Chief Executive Officer and Chief Financial Officer, evaluated~~evaluation of the effectiveness of our internal control over financial reporting, we excluded Danimer Catalytic Technologies in our evaluation during the three-month period ended March 31, 2022. We are in the process of incorporating Danimer Catalytic Technologies into our system of internal control over financial reporting.

We maintain disclosure controls and procedures ~~as of the end of the period covered by this Quarterly Report on Form 10-Q. Our management and our Chief Executive Officer and Chief Financial Officer concluded~~ that ~~our disclosure controls and procedures were effective in providing them with material~~are designed to ensure that information ~~relating to the Company and its consolidated subsidiaries~~ required to be disclosed in the reports we file or submit under the Exchange Act ~~except with respect~~are recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our ~~accounting policy related~~management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosures.

We have evaluated the ~~accounting~~effectiveness of our disclosure controls and procedures for ~~equity~~the three month period ended March 31, 2022. Based upon that evaluation, our principal executive officer and ~~liability instruments (including those with warrants)~~principal financial officer concluded that, as of the date of this report, our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) were not effective due to ~~determine proper accounting~~material weaknesses in ~~accordance with GAAP (e.g., determine whether liability or equity classification and measurement is appropriate).~~our internal control over financial reporting that were disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021.

~~In connection with correcting our accounting for equity and liability instruments (including~~Other than the ~~private warrants assumed by us as part of the Business Combination), we~~remediation efforts discussed below, there have implemented additional review procedures, additional training and enhancements to the accounting policy related to the accounting for equity and liability instruments (including those with warrants) to determine proper accounting in accordance with GAAP (e.g., determine whether liability or equity classification and measurement is appropriate).

~~There were~~been no ~~other~~ changes in our internal control over financial reporting ~~as identified~~(as defined in ~~connection with the evaluation required by~~ Rule ~~13a-15(d) and Rule 15d-15(d) of~~13a-15(f) under the Exchange ~~Act,~~Act) that occurred during the three month period ended ~~June 30, 2021~~March 31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

As previously described in Part II, Item 9A of our Annual Report on Form 10-K for the year ended December 31, 2021, we began implementing remediation plans to address the material weaknesses referenced above. The weaknesses will not be considered remediated until the applicable controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively.

~~On May 14, 2021 a class action complaint was filed by Darryl Keith Rosencrants~~Refer to the information provided in Note 15 to the ~~United States District Court for~~Notes to the ~~Eastern District~~Condensed Consolidated Financial Statements presented in Part I, Item 1. of New York, on May 19, 2021 a class action complaint was filed by Elizabeth and John Skistimas in the United States District Court for the Eastern District of New York, on May 18, 2021 a class action complaint was filed by Carlos Caballeros in the United States District Court for the Middle District of Georgia and on May 18, 2021 a class action complaint was filed by Dennis H. Wilkins also in the United States District Court for the Middle District of Georgia. Each plaintiff or plaintiffs brought the action individually and on behalf of all others similarly situated against the Company and/or Stephen E. Croskrey, John A. Dowdy, III, John P. Amboian, Richard J. Hendrix, Christy Basco, Philip Gregory Calhoun, Gregory Hunt, Isao Noda and Stuart W. Pratt (collectively, “Defendants”).this report.

The alleged class varies in each case but covers all persons and entities other than Defendants who purchased or otherwise acquired securities of the Company between October 5, 2020 and May 4, 2021 (the “Class Period”). Plaintiffs are seeking to recover damages caused by Defendants’ alleged violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the 1934 Act, and Rule 10b-5 promulgated thereunder. The complaints are substantially similar and are each premised upon various allegations that throughout the Class Period, Defendants made materially false and misleading statements regarding, among other things, the Company’s business, operations and compliance policies.

On July 29, 2021, the Georgia court transferred the Georgia cases to New York, motions to consolidate are pending and it is expected that all four class actions will be consolidated into a single lawsuit in the Eastern District of New York. When a consolidated class action complaint is filed, Defendants intend to make a motion to dismiss.

On May 24, 2021, a shareholder derivative lawsuit was filed in the Court of Chancery of the State of Delaware by Richard Delman on behalf of the Company, alleging breach of fiduciary duty against the Company’s directors. That lawsuit has been stayed pending the outcome of Defendants’ motion to dismiss the securities class actions.

The above complaints repeat certain allegations which are already in the public domain. Defendants deny the allegations of the complaints, believe the lawsuits are without merit and intend to defend them vigorously.

There have been no material changes in our risk factors from those disclosed in Part I, Item 1A. of our Annual Report on Form ~~10-K/A~~10-K for the year ended December 31, ~~2020 and Item 1A. of our Quarterly Report on Form 10-Q for the period ended March 31, 2021 other than as follows.~~2021.

We qualify as an “emerging growth company” within the meaning of the Securities Act, and if we take advantage of certain exemptions from disclosure requirements available to emerging growth companies, it could make our securities less attractive to investors and may make it more difficult to compare our performance to the performance of other public companies.

Since the market value of our outstanding securities held by non-affiliates on June 30, 2021 exceeded $700 million, we expect to be deemed a “large accelerated filer,” as defined by the SEC, on January 1, 2022. As a result, our Form 10-K for the year ending December 31, 2021 will be subject to auditor attestation over our internal controls over financial reporting as required by Section 404(b) of the Sarbanes-Oxley Act. Compliance with Section 404(b) will require a significant amount of management's time and we plan to make material expenditures on information technology, process improvement, headcount additions, and consulting expense in order to comply by the end of this year. There can be no assurance that we will succeed in these efforts, and if we do not, the disclosure of one or more material weaknesses is possible. In such a case, the market value of our common stock could be negatively affected.

~~As a large accelerated filer, we will also have to file a more expansive Definitive Proxy Statement on Form DEF14A, which will require additional time and expense as well.~~

There may be many challenges to integrating acquired businesses into our Company, including eliminating redundant operations, facilities and systems, coordinating management and personnel, retaining key employees, managing different corporate cultures and achieving cost reductions and cross-selling opportunities. We may not be able to meet these challenges.

Item 2. ~~Unregistered Sales of Equity Securities and Use of Proceeds~~UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

On August 11, 2021, the Company completed the previously announced acquisition of Novomer, Inc. pursuant to the Merger Agreement. Pursuant to the terms of the Merger Agreement, the Company acquired 100% of the equity interests of Novomer in exchange for approximately $152 million in cash, subject to certain purchase price adjustments. The Company financed the Acquisition from cash on hand. The foregoing description of the Merger Agreement is not intended to be complete and is qualified in its entirety by the complete text of the Merger Agreement, which is included as Exhibit 2.1 to this Report and is incorporated herein by reference.

On August 12, 2021, the Company entered into an agreement with Stuart Pratt, a director of the Company, pursuant to which, in the event that the Company is unable for any reason to issue to Mr. Pratt stock options, restricted stock awards, performance stock awards, other equity based awards or shares of common stock, whether underlying such awards or otherwise, that the Company has contractually agreed to in prior agreements with Mr. Pratt, then the Company shall be contractually obligated to pay to Mr. Pratt, upon the vesting of any such awards, an amount in cash equal to the notional value that each such stock option, restricted stock award, performance stock award or other equity based award would have had on the date of such vesting as though it had been granted to Mr. Pratt on the date such other agreement giving rise to such award was entered into; provided that any such cash payment shall be payable over a period of three years in equal quarterly installments, starting with the date of the vesting of such award.

~~# Indicates management contract or compensatory plan or arrangement~~with this quarterly report

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


Delaware	84-1924518
( State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
140 Industrial Boulevard Bainbridge, GA	39817
(Address of principal executive offices)	(Zip Code)


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A Common stock, $0.0001 par value per share	DNMR	New York Stock Exchange


Large accelerated filer	☐	☒	Accelerated filer	☐
Non-accelerated filer	☐	☒	Smaller reporting company	☒☐
Emerging growth company	☒☐


		Page

PART I.	FINANCIAL INFORMATION

Item 1.	Financial Statements (Unaudited)	2
	Condensed Consolidated Balance Sheets	2
	Condensed Consolidated Statements of Operations	3
	Condensed Consolidated Statements of Stockholders' Equity	4
	Condensed Consolidated Statements of Cash Flows	5
	Notes to Condensed Consolidated Financial Statements	6
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	1618
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	2624
Item 4.	Controls and Procedures	2625

PART II.	OTHER INFORMATION	26

Item 1.	Legal Proceedings	26
Item 1A.	Risk Factors	26
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	27
~~Item 5.~~	~~Other Information~~	2726
Item 6.	Exhibits	2826
Signatures		2927


	Three Months Ended June 30,						Six Months Ended June 30,
(in thousands, except share and per share data)	2021			2020			2021			2020
Revenue:
Products	$	11,294		$	10,576		$	22,318		$	19,755
Services		3,177			1,297			5,334			2,716
Total revenue		14,471			11,873			27,652			22,471

Costs and expenses:
Cost of revenue		12,460			8,441			24,185			15,870
Selling, general and administrative		19,079			2,828			29,199			5,808
Research and development		3,975			2,128			6,594			3,375
(Gain) loss on sale of assets		33			(9	)		33			(9	)
Total costs and expenses		35,547			13,388			60,011			25,044
Loss from operations		(21,076	)		(1,515	)		(32,359	)		(2,573	)

Nonoperating income (expense):
Gain (loss) on remeasurement of private warrants		58,740			0			(21,957	)		0
Interest expense, net		(222	)		(384	)		(422	)		(1,097	)
Gain on forgiveness of debt		1,776			0			1,776			0
Loss on loan extinguishment		0			0			(2,604	)		0
Other income (expense), net		30			99			80			189
Total nonoperating income (expense)		60,324			(285	)		(23,127	)		(908	)
Income (loss) before income taxes		39,248			(1,800	)		(55,486	)		(3,481	)
Income tax expense		0			0			0			0
Net income (loss)	$	39,248		$	(1,800	)	$	(55,486	)	$	(3,481	)

Net income (loss) per share:
Basic net income (loss) per share	$	0.44		$	(0.06	)	$	(0.64	)	$	(0.12	)
Diluted net income (loss) per share	$	0.39		$	(0.06	)	$	(0.64	)	$	(0.12	)

Weighted average number of shares used to compute: (1)
Basic net income (loss) per share		88,806,086			29,005,309			86,760,615			28,386,948
Dilutive effect of warrants and stock options		12,718,858			0			0			0
Diluted net income (loss) per share		101,524,944			29,005,309			86,760,615			28,386,948

(1) 2020 Amounts retroactively restated for Business Combination


☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


	Estimated
	Useful Life	June 30,			December 31,
(in thousands)	(Years)	2021			2020
Land and improvements	20	$	92		$	92
Leasehold improvements	Shorter of useful life or lease term		21,021			20,932
Buildings	15-40		2,089			2,089
Machinery and equipment	5-20		82,489			64,164
Motor vehicles	7-10		874			693
Furniture and fixtures	7-10		229			221
Office equipment	3-10		2,110			2,089
Construction in progress	N/A		74,771			36,146
			183,675			126,426
Accumulated depreciation and amortization			(23,692	)		(19,631	)
Property, plant and equipment, net		$	159,983		$	106,795


(in thousands)
Balance at December 31, ~~2020~~	$	(~~82,860~~	)
~~Loss on remeasurement of Private Warrants~~		(~~80,697~~	)
~~Fair value of Private Warrants sold~~		~~13,922~~
~~Balance at March 31, 2021~~		(~~149,635~~	)
~~Gain on remeasurement of Private Warrants~~		~~58,740~~
~~Fair value of Private Warrants sold~~		~~31,593~~
~~Balance at June 30,~~ 2021	$	(~~59,302~~9,578	)
Gain on remeasurement of private warrants		4,995
Balance at March 31, 2022	$	(4,583	)


	As Of			Three Months Ended						Six Months Ended							As Of
	June 30, 2021			June 30, 2021						June 30, 2021							December 31, 2020
Share price of our common stock	$	25.05		$	17.45	-	$	38.33		$	17.45		-	$	44.26		$	23.51
Expected annual dividend yield (1)		0	%					0	%						0	%		0	%
Expected volatility (2)		40	%					40	%						40	%		40.0	%
Risk-free rate of return (3)		0.76	%					0.76	%		0.76	%	-		0.85	%		0.36	%
Expected warrant term (years) (4)		4.50			4.50	-		4.73			4.50		-		4.99			4.99
Fair value determined per warrant	$	15.14		$	8.53	-	$	27.82		$	8.53		-	$	33.65		$	13.81


	For the Six Months Ended June 30,
	2021							2020
(in thousands)	Contract Asset		Contract Liability			Total Revenue Recognized		Contract Asset		Contract Liability			Total Revenue Recognized
Beginning balance	$	0	$	(2,455	)			$	0	$	(4,580	)
Revenue recognized		1,529		3,251		$	4,780		0		1,256		$	1,256
Unearned consideration received		0		(1,618	)				-		(350	)
Ending balance	$	1,529	$	(822	)	$	4,780	$	0	$	(3,674	)	$	1,256


	For the Six Months Ended June 30,
(in thousands)	2021			2020
Net cash (used in) provided by operating activities	$	(22,641	)	$	(10,389	)
Net cash (used in) investing activities	$	(51,566	)	$	(19,070	)
Net cash provided by financing activities	$	111,189		$	28,193


	·	~~Net proceeds from warrant exercises of $138.2 million~~
	·	~~Proceeds from the exercise of stock options of $2.4 million~~


	·	~~Proceeds of $24.9 million from the issuance of common stock, net of issuance costs~~
	·	~~Proceeds from issuance of long term debt of $4.0 million~~


Exhibit ~~Number~~ No.		Description
~~2.1~~31.1*		Agreement and Plan of Merger, dated July 28, 2021, by and among the Company, Merger Sub, Novomer and Stockholders' Representative (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K (Commission File No. 001-39280) filed on August 3, 2021).
~~10.1#~~		Amended and Restated Employment Agreement, dated as of July 23, 2021, between Danimer Scientific, Inc. and Stephen E. Croskrey (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K (Commission File No. 001-39280) filed on July 29, 2021).
~~10.2#~~		Performance Stock Agreement, dated July 23, 2021, between the Company and Stephen E. Croskrey (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K (Commission File No. 001-39280) filed on July 29, 2021).
~~10.3#~~		Stock Option Agreement, dated July 23, 2021, between the Company and Stephen E. Croskrey.(incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K (Commission File No. 001-39280) filed on July 29, 2021).
~~10.4*#~~		~~Letter Agreement, dated August 12, 2021, between the Company and Stuart Pratt~~
31.1*		Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*		Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of ~~2002~~2002.
32.1*		Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS		Inline XBRL Instance Document ~~��~~– the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.
101.SCH		Inline XBRL Taxonomy Extension Schema ~~Document~~
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)


	Danimer Scientific, Inc.

Date: ~~August 16, 2021~~May 10, 2022	By:	/s/ Stephen E. Croskrey
		Stephen E. Croskrey
		Chief Executive Officer
		(Principal Executive Officer)

Date: ~~August 16, 2021~~May 10, 2022	By:	/s/ ~~John A Dowdy, III~~Michael A. Hajost
		~~John A Dowdy, III~~Michael A. Hajost
		Chief Financial Officer
		(Principal Financial Officer and Principal Accounting Officer)